

Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action Plan to address Actions for the next 5 years

March 27, 2009

This information is distributed solely for the purpose of pre dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the National Institute for Occupational Safety and Health. It does not represent and should not be construed to represent any agency determination or policy.

Table of contents

1		
2		
3	Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action Plan to address	
4	Actions for the next 5 years.....	1
5	Recommendation 1.1: Understanding influenza transmission.....	2
6	Recommendation 1.2: Commit to worker safety and appropriate use of PPE.....	3
7	Recommendation 1.3: Innovate and strengthen PPE design, testing and certification.....	4
8	FY 09 PPT Program Activities and Projects Related to Recommendations	7
9	Appendix A: PPE for HCW Action Plan-081908.doc Docket# 129	A-1
10	Appendix B: Respirator & Surgical Mask Efficacy from Cough Aerosols.....	B-1
11	Appendix C: Response to NIOSH Docket 129 Comments	C-1
12	Appendix D: List of Acronyms.....	D-1
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		

31 **Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action**
32 **Plan to address Actions for the next 5 years**

33
34 In the event of pandemic influenza, personal protective equipment, including disposable
35 particulate respirators and surgical facemasks, will be one of several public health interventions
36 that make up the first line defense against human-to-human transmission of the virus.

37
38 Subsequently, the National Institute for Occupational Safety and Health (NIOSH) National
39 Personal Protective Technology Laboratory (NPPTL) requested the Institute of Medicine (IOM)
40 of the National Academies (NA) examine the issues regarding PPE for healthcare workers in the
41 event of pandemic influenza. The IOM issued a report, Assessment of Pandemic Preparedness
42 and the associated PPE needs for Healthcare Workers (2007) in September 2007 to provided
43 recommendations to NPPTL. This plan responds the recommendations provided by the IOM in
44 the report.

45
46 The IOM report, Preparing for an Influenza Pandemic: Personal Protective Equipment for
47 Healthcare Workers, September 2007, defines an urgent need to address the lack of preparedness
48 regarding effective PPE for use in an influenza pandemic. The IOM report identifies
49 recommendations for research and policy actions in three critical areas:

- 50
51
 - Understanding influenza transmission.
 - Commit to worker safety and appropriate use of PPE.
 - Innovate and strengthen PPE design, testing and certification.

52
53
54
55 These three areas are defined and examined in detail as “Issues” below.

56
57 The IOM recommendations in these areas are extensive, requiring the involvement of numerous
58 federal agencies, the private sector and international partners. The report recommends the
59 Department of Health and Human Services (DHHS) lead a focused research effort to facilitate
60 understanding of the transmission and prevention of seasonal and pandemic influenza. NIOSH
61 and the Personal Protective Technology (PPT) Program are charged with assisting in this effort
62 as it relates to understanding transmission among healthcare workers, and conducting research to
63 design and promote the appropriate use of PPE.

64
65 The IOM report recommends the expansion of existing research, such as the hospital influenza
66 transmission study currently funded by Pandemic Flu Preparedness funds, as well as the
67 initiation of new projects to possibly be funded through the National Occupational Research
68 Agenda (NORA) process. Key activities to be conducted by NIOSH are outlined below, in
69 accordance with the three critical research areas outlined in the IOM report. Each
70 recommendation identifies current activities in progress within NIOSH and subsequent activities
71 to be conducted.

72
73 This plan summarizes the recommendations and the actions planned for the next five years to
74 address the recommendations in the main document. Appendix A is the most recent version of
75 the more detailed action plan which describes the research needs in greater detail over a ten year
76 timeline. Appendix B provides an overview of the NIOSH Cough Study described in Appendix

77 A. Appendix C provides the response to the comments submitted to NIOSH Docket 129 on this
78 subject.

79

80 **Recommendation 1.1: Understanding influenza transmission**

81

82 **Desired Outcome:** The mechanisms and routes of human-to-human influenza
83 transmission are understood.

84

85 The current knowledge of key aspects of influenza transmission is rudimentary. Increased
86 understanding is required on the extent of droplet, aerosol, and contact transmission, and the
87 optimum ways to prevent transmission. Research initiatives are needed to address these matters
88 and the viability/infectivity of the airborne virus. As these issues are more clearly understood,
89 successful mitigation and prevention strategies can be developed and deployed.

90

91 **ACTIVITY 1.1.1: Research to develop an understanding of influenza transmission.**

92

93 ***ACTION STEP 1.1.1.1: Measure the size and quantity of aerosol droplets produced by*** 94 ***people when they cough.***

95

96 *Summary: Measure the size and quantity of aerosol droplets produced by people*
97 *when they cough – Healthy volunteer subjects and volunteer subjects with influenza will*
98 *be asked to cough into a collection bag. Aerosol measurement instruments will then*
99 *draw the air from the bag and measure the quantity and size of airborne droplets that are*
100 *produced. (PPE HCW AP 1.3.3)*

101

102 ***ACTION STEP 1.1.1.2: Measure the amount and size of airborne particles containing*** 103 ***influenza virus in a hospital. (PPE HCW AP 1.3.4)***

104

105 *Summary: Measure the amount and size of airborne particles containing*
106 *influenza virus in a hospital – During the 2008 influenza season, healthcare workers in a*
107 *hospital emergency department wore personal aerosol samplers that collect airborne*
108 *material from the environment while they worked. Stationary aerosol samplers were also*
109 *placed in the waiting rooms, reception area and two exam rooms. Preliminary results*
110 *indicate that influenza virus was detected in 3 of 14 personal samplers and 10 of 98*
111 *stationary samplers, and that 50% of the virus was on particles less than 4 µm in*
112 *diameter (these particles are small enough to stay airborne for half an hour or more and*
113 *to be drawn deep into the lungs). An expanded study is planned for next year.*

114

115 ***ACTION STEP 1.1.1.3: Simulate the exposure of a healthcare worker to an infectious*** 116 ***aerosol. (PPE HCW AP 1.3.6.1.2)***

117

118 *Summary: Simulate the exposure of a healthcare worker to an infectious aerosol –*
119 *A simulated exam room is being created with a cough aerosol simulator (simulating a*
120 *coughing patient with influenza) and a breathing mannequin (simulating a healthcare*
121 *worker) to test how well healthcare workers are protected from cough-generated*
aerosols. The breathing mannequin can be outfitted with a mask or respirator to
simulate different types of respiratory protection. As part of this work, the viability
(infectivity) of a surrogate laboratory strain of influenza will be studied. Experiments are

122 *planned to determine the viability of the virus in an aerosol and the effect of capture in*
123 *the sampler on virus viability.*

124

125 **Recommendation 1.2: Commit to worker safety and appropriate use of PPE**

126

127 **Desired Outcome:** A culture of safety is evident in both individuals and organizations
128 within the healthcare community.

129

130 Appropriate PPE use and HCW safety should be a priority for all individuals within the
131 healthcare workplace, as well as being made an integral part of the operation culture of their
132 parent organizations. A primary way to bring about these desired results is to emphasize the
133 correct use (and disposal) of PPE during patient care across healthcare employees and
134 management through training and accreditation.

135

136 Another appropriate mechanism involves conducting demonstration projects on PPE compliance
137 and use. These efforts can be used to identify best practices for improving PPE use. Publication
138 and broad dissemination of the results of these projects can ensure the proliferation of successful
139 PPE strategies.

140

141 Finally, additional research is needed to improve the understanding of how human factors and
142 behavioral issues related to the ease and effectiveness of PPE use for extended periods of time
143 and during diverse work environments affect PPE use and compliance.

144

145 **ACTIVITY 1.2.1: Research, training, and interventions to ensure the appropriate use of** 146 **PPT.**

147

148 ***ACTION STEP 1.2.1.1: Collaborating to conduct research and disseminate research*** 149 ***findings.*** (PPE HCW AP 1.1.1)

150

151 *Summary: Collaboration with other federal agencies, healthcare organizations,*
152 *standards development organizations and other stakeholders is a critical element for*
153 *successful implementation of the IOM recommendations. The PPT Program will actively*
154 *seek stakeholder participation and involvement in the actions of the program and will*
155 *strive to maintain transparency in carrying out program actions. Information on best*
156 *practices and other research findings will be disseminated via the NIOSH website,*
157 *printed literature, conference participation, standards development meetings and annual*
158 *stakeholder meetings. Key findings will also be translated into documents to be shared*
159 *with healthcare workers and employers directly.*

159

160 ***ACTION STEP 1.2.1.2: Training for healthcare professionals.*** (PPE HCW AP 6.4.2)

161

162 *Summary: In 2008, NIOSH initiated an Occupational Medicine rotation for*
163 *Internal Medicine and Family Medicine residents to enhance their skills and knowledge*
164 *of PPE. The one-day rotation includes shadowing an Occupational Medicine physician,*
165 *respirator fit testing practice, and audiogram performance and interpretation. Oversight*
166 *of the rotation is provided by the NIOSH NPPTL Research Medical Officer. NIOSH will*
167 *expand this program to further advance PPE training for healthcare workers.*

167

168 ***ACTION STEP 1.2.1.3: Surveillance of PPE usage.*** (PPE HCW AP 1.3.6.1.3)

169 *Summary: The PPT Program, in partnership with healthcare organizations, will*
170 *develop and strengthen the use of surveillance data to identify priorities, trends and*
171 *emerging issues associated with the use of PPE in the workplace. Information gathered*
172 *will be used to establish a baseline on PPE usage, develop performance measures,*
173 *sharpen the focus of NIOSH research, and aid in the development of a more effective and*
174 *active dissemination program.*
175

176 **Recommendation 1.3: Innovate and strengthen PPE design, testing and**
177 **certification**

178
179 **Desired Outcome:** Effective PPE, with initial emphasis on filtering facepiece respirators
180 (FFR), are designed, tested, certified, and readily available for use by the healthcare workforce,
181 for routine and non-routine applications.
182

183 The use of PPE in any specific workplace environment places unique demands on the design and
184 engineering of these products. This is of particular importance in the healthcare industry where
185 these products have to be focused on interactions between the workers and their patients. In
186 these circumstances, the concerns are not only that the workers not be infected by the patients,
187 but also that they (the workers) also do not transmit infections to subsequent patients through the
188 equipment they use to protect themselves.
189

190 An integrated effort is needed to fully understand the unique requirements of HCWs and to
191 develop innovative materials, technologies, and products that can meet their needs, as well as
192 those of their patients.
193

194 Core issues regarding the responsibilities of federal agencies and organizations have to be
195 clarified. Further, increasing the use of testing in the pre-market phase and conducting post-
196 marketing evaluations is vital to the development and effective use of such products.
197

198 Some of the key scientific questions to be addressed by this research program include (note:
199 several of the research questions pertaining to Recommendation 4 of the PPT Implementation
200 Plan (IP) are relevant here as well):
201

- 202 – Can PPE (in particular single-use FFRs) be decontaminated to remove infectious
203 material and then be safely reused?
- 204 – How effective are the various strategies (e.g., stockpiling, surgical mask overlay,
205 decontamination, etc.) for mitigating the impact of a respirator shortage during a
206 pandemic? Are there best practices that can be shared?
- 207 – What are risks of handling PPE exposed to infectious materials? What is the
208 likelihood of contaminated PPE serving as a fomite? What are the best methods (e.g.,
209 donning/doffing procedures) or technologies (e.g., antimicrobial coatings) for
210 mitigating those risks?
211

212 **ACTIVITY 1.3.1: Research to develop and test PPE.**
213

214 **ACTION STEP 1.3.1.1: Handling and use of contaminated PPE.** (PPE HCW AP 1.3.4
215 and 5.3.10.2)

216 *Summary: Although respirators serve to protect the wearer, concerns exist that*
217 *viruses remaining on a respirator transform it into a fomite that may serve as a vehicle*
218 *for infection of the wearer, or others. The PPT Program will conduct research to assess*
219 *the viability of an influenza surrogate virus on various models of filtering facepiece*
220 *respirators (including respirators with antimicrobial components). Data generated will*
221 *offer important information on fomite-related issues and also allow for the quantification*
222 *of subsequent decontamination effects on the respirator.*

224 **ACTION STEP 1.3.1.2: Strategies for decontamination of PPE.** (PPE HCW AP 1.2.3
225 and 5.3.10.2)

226 *Summary: The availability of FFRs during a pandemic influenza is a subject of*
227 *major concern. Respirator manufacturers have warned that they may not be able to meet*
228 *the anticipated demand. This has placed more emphasis upon the idea of*
229 *decontaminating FFRs for reuse. Research will be planned and conducted to address the*
230 *reusability of FFRs following various types of decontamination (e.g., heat, soap & water,*
231 *chemicals, ultraviolet light, gas sterilization, microwaving). The data will be used to*
232 *categorize the various decontamination agents with respect to their effects on filtration*
233 *performance of the respirator.*

235 **ACTION STEP 1.3.1.3: Protective differences between various types of PPE.** (PPE
236 HCW AP 4.2.1 and 5.3.9)

237 *Summary: Relative performance of N95 and P100 FFRs will be evaluated in*
238 *laboratory protection level studies. The tests will measure total protection provided by*
239 *the respirators assessing all potential leakage paths. Test subjects will wear the*
240 *respirators while performing work at different work levels in order to evaluate*
241 *performance at different breathing rates. Test results would be applicable to virus*
242 *particles, whether aerosol or droplet transmission.*

244 **ACTION STEP 1.3.1.4: PPE systems integration requirements for healthcare workers.**
245 (PPE HCW AP 4.5.1.2 and 3.0 and PPT IP 4)

246 *Summary: Respirators utilized in healthcare settings were not designed for that*
247 *particular venue. Therefore, there are features of respirators that do not necessarily lend*
248 *themselves well to the healthcare environment. The PPT Program, in conjunction with*
249 *the Veterans' Health Administration (VA) and academia, initiated the Project Better*
250 *Respirator Equipment and Technology for Healthcare Employees (BREATHE). Currently*
251 *in its developmental stages, this endeavor will first bring together a working group to*
252 *address respirator characteristics germane to healthcare workers (e.g., speech*
253 *intelligibility, visibility, hearing, etc.) with the goal of identifying features that would*
254 *enhance respirator performance in the healthcare setting. The second stage of this*
255 *project will consist of presenting the recommendations to respirator manufacturers with*
256 *the intent of developing a respirator that is designed specifically with the healthcare*
257 *worker in mind.*

258

259 ***ACTION STEP 1.3.1.5: New materials and innovative technologies.*** (PPE HCW AP
260 4.1 and PPT IP 4.2)

261 *Summary: Application of new materials and innovative concepts in the design and*
262 *development of respirators and other PPE can present an opportunity to improve*
263 *performance of PPE. Innovative application of new technologies such as incorporating*
264 *sensors into PPE to detect breaches and notify users of end of service life and other*
265 *protection information will be explored.*
266

267 ***ACTION STEP 1.3.1.6: Respirator fit test science and pre-use checks research.*** (PPE
268 HCW AP 5.3 and 5.3.1.1 and PPT IP 4.2.1.1)

269 *Summary: Frequency of fit testing research will be performed to assess the rate at*
270 *which respirator fit changes as a function of time, and investigate the factors that affect*
271 *such change. The metric for respirator fit will be the respirator penetration. Pre-use*
272 *check research investigating the efficacy of user seal checks on FFRs will also be*
273 *performed.*
274

275 ***ACTION STEP 1.3.1.7: PPE usage and physiological consequences.*** (PPE HCW AP
276 4.1.2 and PPT IP 4.2)

277 *Summary: The PPT Program will investigate carbon dioxide and oxygen levels in*
278 *healthcare workers who wear respirators for prolonged periods, as would occur in a*
279 *pandemic influenza. If elevated Carbon Dioxide (CO₂) levels or depressed Oxygen (O₂)*
280 *levels are measured that would lead to symptoms, mitigation strategies will be developed.*
281

282 **ACTIVITY 1.3.2: Research to develop evidenced based performance standards.** (PPE
283 HCW AP 2.0)
284

285 ***ACTION STEP 1.3.2.1: Evidence-based performance requirements for PPE in***
286 ***healthcare settings.*** (PPE HCW AP 2.0)

287 *Summary: The PPT Program will work to identify PPE used by healthcare*
288 *workers and the existing performance standards. A quantitative performance analysis*
289 *will be conducted to assess the effectiveness of each type of PPE (gowns, gloves,*
290 *respirators, etc.) in reducing the risk of influenza transmission. The findings combined*
291 *with surveillance data will form the basis for developing enhanced, evidence-based*
292 *performance requirements.*
293

294 **ACTIVITY 1.3.3: Research to conduct PPE evaluations.**
295

296 ***ACTION STEP 1.3.3.1: Pre-market and post-market PPE testing.*** (PPE HCW AP 10.0
297 and 11.0)

298 *Summary: The PPT Program will investigate methods to implement pre- and*
299 *post-market testing of PPE used in healthcare settings. This could include analysis of the*
300 *requirements and use of PPE to identify methods to perform workplace and simulated*
301 *workplace testing to achieve a true assessment of PPE effectiveness. The findings of this*
302 *study could aid in the improvement of PPE design and use.*
303

304 ***ACTION STEP 1.3.3.2: PPE Certification.*** (PPT IP 1.3.1.1)

305 *Summary: The IOM report states: "The development and implementation*
306 *of certification processes should be explored by NIOSH [PPT Program] and the Food*
307 *and Drug Administration (FDA), with certification testing occurring in the NPPTL*
308 *laboratory or by a process determined to be best suited for increased pre-market testing."*
309 *As stated in PPT IP 1.3.1.1, a workshop similar to the PPE for HCW workshop will be*
310 *organized by IOM to address options for PPT certification. The workshop is anticipated to*
311 *be a Fiscal Year (FY) 2010 activity.*

312
313
314 **FY 09 PPT Program Activities and Projects Related to Recommendations**

315
316 The PPT Program has identified the FY09 PPT activities that support this recommendation. This
317 diverse portfolio of research addresses critical aspects of the research gaps identified above in
318 action steps 1-1, 1-2, and 1-3. All of these research activities are conducted by our intramural
319 staff in collaboration with various partners and stakeholders. Several projects work closely with
320 the various American Society for Testing and Materials (ASTM) International, International
321 Organization for Standardization (ISO), and National Fire Protection Association (NFPA)
322 committees to transition PPT intramural program outputs into recognized standards and test
323 methods. Project BREATHE cuts across several of the research gaps by seeking to develop a
324 respirator optimized for the healthcare sector featuring better integration with other PPE, less job
325 interference, better fit, and improved comfort. Several projects are focused on understanding
326 critical issues related to concerns of a possible respirator shortage caused by a pandemic. For
327 example, one project involves collaboration with the Department of Defense (DoD) Air Force
328 research lab (AFRL), FDA and several universities with funding provided by the DoD Technical
329 Support Working Group (TSWG) to study decontamination/reuse of FFRs. Establishing a better
330 understanding of respirator fit and performance are the goals of several other projects. All
331 program activities related to this plan can be located at the following link:
332 <http://www.cdc.gov/niosh/programs/ppt/projects.html>. Approximately \$400 Thousand (K)
333 discretionary funds are dedicated in FY09 to support these initiatives.

Appendix A: PPE for HCW Action Plan-081908.doc Docket# 129

Summary

During an influenza pandemic, healthcare workers will be on the front lines delivering care to patients and preventing further spread of the disease. As the nation prepares for pandemic influenza, multiple avenues for protecting the health of the public are being carefully considered, ranging from rapid development of appropriate vaccines to quarantine plans should the need arise for their implementation. One vital aspect of pandemic influenza planning is the use of PPE—the respirators, gowns, gloves, face shields, eye protection, and other equipment that will be used by healthcare workers and others in their day-to-day patient care responsibilities.

However, efforts to appropriately protect healthcare workers from illness or from infecting their families and their patients are greatly hindered by the scarcity of data on the transmission of influenza and the challenges associated with training and equipping healthcare workers with effective personal protective equipment. Due to this lack of knowledge on influenza transmission, it is not possible at the present time to definitively inform healthcare workers about what PPE is critical and what level of protection this equipment will provide in a pandemic. The outbreaks of severe acute respiratory syndrome (SARS) in 2003 have underscored the importance of protecting healthcare workers from infectious agents. The surge capacity that will be required to reduce mortality from a pandemic cannot be met if healthcare workers are themselves ill or are absent due to concerns about PPE efficacy. The increased emphasis on healthcare PPE and the related challenges anticipated during an influenza pandemic necessitate prompt attention to ensure the safety and efficacy of PPE products and their use.

In 2006, the IOM Committee on Personal Protective Equipment (COPPE) determined that there is an urgent need to address the lack of preparedness regarding effective PPE for use in an influenza pandemic. Subsequently, NPPTL at NIOSH asked the IOM to examine issues regarding PPE for healthcare workers in the event of pandemic influenza. The IOM committee was charged with examining research directions, certification and the establishment of standards, and risk assessment issues specific to personal protective equipment for healthcare workers during an influenza pandemic.

The IOM provided three overarching conclusions and a series of recommendations for maximizing the opportunity to incorporate PPE into influenza pandemic research. The committee also provided recommendations regarding future research opportunities. The twelve recommendations made to address the three overarching conclusions are as follows:

Understand Influenza Transmission

- Initiate and Support a Global Influenza Research Network

Commit to Worker Safety and Appropriate Use of PPE

- Emphasize Appropriate PPE Use in Patient Care and in Healthcare Management, Accreditation, and Training
- Identify and Disseminate Best Practices for Improving PPE Compliance and Use
- Increase Research and Research Translation Efforts Relevant to PPE Compliance

382 *Innovate and Strengthen PPE Design, Testing, and Certification*

- 383 • Define Evidence-Based Performance Requirements (Prescriptive Standards) for PPE
- 384 • Adopt a Systems Approach to the Design and Development of PPE
- 385 • Increase Research on the Design and Engineering of the Next Generation of PPE
- 386 • Establish Measures to Assess and Compare the Effectiveness of PPE
- 387 • Ensure Balance and Transparency of Standards-Setting Processes
- 388 • Strengthen Pre-market Testing of PPE for Healthcare Workers
- 389 • Strengthen Post-market Evaluation of PPE for Healthcare Workers
- 390 • Coordinate Efforts and Expand Resources for Research and Approval of PPE

391

392 One of the challenges for the healthcare field is to clearly understand the differences between
393 respirators and medical masks as well as their appropriate uses. Medical masks (the term is used
394 in this report to encompass surgical masks and procedure masks) are loose-fitting coverings of
395 the nose and mouth designed to protect the patient from the cough or exhaled secretions of the
396 physician, nurse, or other healthcare worker. Medical masks are not designed or certified to
397 protect the wearer from exposure to airborne hazards. They may offer some limited, as yet
398 largely undefined, protection as a barrier to splashes and large droplets. However, because of the
399 loose-fitting design of medical masks and their lack of protective engineering, medical masks are
400 not considered personal protective equipment.

401

402 A terminology issue has further confused and blurred the boundary between medical masks and
403 respirators. The term “respirator” is commonly used in the healthcare field to refer to two
404 different medical devices: (1) the personal protective equipment discussed in this report that is
405 used to reduce the wearer’s risk of inhaling hazardous substances and (2) the mechanical
406 ventilator device that is used to ventilate patients in respiratory failure (such devices are more
407 properly called “ventilators” than “respirators”). This dual (medical and occupational) use of the
408 term respirator has prompted many healthcare workers to refer to PPE respirators as masks,
409 thereby confounding the important distinctions between medical masks and respirators.

410

411 Protection of the healthcare worker against infectious disease can also involve gloves, eye
412 protection, face shields, gowns, and other protection. For the most part, these products are
413 designed to provide a barrier to microbial transfer with particular attention to protecting the
414 wearer’s mucous membranes. The extent of liquid penetration is a major issue with gowns and
415 gloves. Comfort and wearability issues include the breathability of the fabric or material and
416 biocompatibility or sensitivity to avoid contact dermatitis and other skin irritations. Issues related
417 to viral survival on contaminated surfaces and objects, viral penetrance, and reusability remain to
418 be explored as do considerations about how best to integrate the use of the various types of
419 protective equipment to ensure that they integrate effectively (e.g., the respirator and eye
420 protection).

421

422 More than 14 million workers in the United States (approximately 10 percent of the U.S.
423 workforce) are employed in the healthcare field. Thus, it’s important that we protect those
424 workers on the front lines with the best available PPE and prevention methods to handle an
425 influenza pandemic. To that end, it is imperative that a global influenza research network be
426 established to examine the influenza transmission issues that directly affect the PPT Program.
427 Some of the major questions that need answers are:

- 428
- 429 • What are the major modes of transmission? How much does each mode of transmission
- 430 contribute individually or with other methods of transmission?
- 431 • What is the size distribution of particles expelled by infectious individuals, and how does
- 432 that continuum of sizes affect transmission?
- 433 • Can infection take place through mucous membranes or conjunctiva exposure?
- 434 • What is the role of UV light, humidity, temperature, pressure differentials, air flow and
- 435 exchange and ventilation in preventing transmission?
- 436 • and How effective is each type of PPE (gowns, gloves, respirators, etc.) in reducing the
- 437 risk of influenza transmission? Should other than respirator PPE be certified, if so who's
- 438 responsibility is it?
- 439

440 NIOSH/NPPTL has the overall management responsibility for the NIOSH PPT Program and is

441 responding to the IOM report by developing an action plan for addressing the issues and

442 recommendations within the PPT program domain described in the report. The action plan

443 provides both a near term and long term strategy for influenza pandemic research, development,

444 and investigative testing for the PPT Program. The action plan is structured to align with the

445 recommendations outlined in the IOM report, *Preparing for an Influenza Pandemic: PPE for*

446 *Healthcare Workers, 2008*. Each recommendation identifies current activities in progress within

447 the NIOSH PPT Program and subsequent activities which should be considered for both near

448 term and long term implementation. Associated references and web links are provided for

449 ongoing activities where available. Each text description is accompanied by a flow chart which

450 provides a pictorial representation of the information described in the associated text. Associated

451 Gantt Charts identifying anticipated timelines for conducting the activities in response to each

452 recommendation follow the flow charts. The PPT Program ongoing and potential future

453 activities are highlighted in yellow. The action plan addresses implementation of research

454 recommendations in the workplace. The following steps are being taken to develop the action

455 plan:

- 456 • Assess the IOM recommendations to identify actions within the PPT Program domain
- 457 • Review on-going and proposed PPT Program activities
- 458 • Assess the IOM recommendations to determine if existing data are available to make
- 459 decisions on whether the recommendations should be implemented near or long term
- 460 • Apprise applicable organizations to disseminate actions outside the PPT Program
- 461 domain.
- 462 • Solicit stakeholder input on action plan.
- 463 • Review on-going activities in NIOSH, academia, government, and industry related to
- 464 influenza pandemic preparedness.
- 465 • Prioritize activities in response to recommendations within the PPT Program domain
- 466 • Determine if new initiatives for PPT Program should be managed through intra- or extra-
- 467 mural processes
- 468 • Schedule project proposals into the PPT Program strategic planning process
- 469 • Develop final PPE for HCW Action Plan
- 470 • Implement PPE for HCW Action Plan
- 471

472 Being ready for an influenza pandemic—having the necessary resources to minimize morbidity
473 and mortality—is the goal of ongoing global efforts in many areas of endeavor. Since healthcare
474 workers are essential for providing patient care during a pandemic, the personal protective
475 equipment that can protect these workers from becoming infected or from transmitting infection
476 is a vital part of these efforts. Healthcare worker safety is essential for patient safety and patient
477 care. Being prepared for an influenza pandemic places a priority on protecting the healthcare
478 workforce.

479

480 I. Introduction

481

482 In 2005, the NIOSH NPPTL asked the IOM to form a standing committee to provide strategic
483 guidance in addressing Personal Protective Equipment issues for workers. One issue the
484 committee deemed of high importance is PPE for HCW in the event of pandemic influenza.
485 NPPTL then funded a 12 month study conducted by an adhoc IOM committee. The IOM
486 committee was charged with examining research directions, certification and the establishment
487 of standards, and risk assessment issues specific to PPE for healthcare workers during an
488 influenza pandemic.

489

490 The IOM completed the study and issued the report *Preparing for an Influenza Pandemic:
491 Personal Protective Equipment for Healthcare Workers* to the PPT Program in September 2007.
492 The IOM provided three overarching conclusions and a series of recommendations for
493 maximizing the opportunity to incorporate PPE into influenza pandemic research. The committee
494 also provided recommendations regarding future research opportunities. The three overarching
495 conclusions are stated here:

- 496 • Understanding influenza transmission—Current knowledge is rudimentary regarding the
497 mechanisms and routes of human-to-human influenza transmission (Chapter 2), but with
498 dedicated resources and new technologies, more can be known about the extent of
499 droplet, aerosol, and contact transmission and the optimum ways to prevent transmission.
- 500 • Making the commitment to worker safety and appropriate use of PPE—Healthcare
501 workers often do not wear the protective equipment needed to ensure that they are
502 adequately protected from exposure to hazardous agents including infectious disease.
503 Strengthening the commitment of healthcare employers to worker safety and enhancing
504 the culture of safety in the workplace involve both an organizational and an individual
505 commitment to the appropriate use of PPE (Chapter 4).
- 506 • Designing, testing, and certifying effective PPE for the healthcare workforce—Using
507 PPE in a healthcare workplace places specific demands on the design and engineering of
508 these products that are particularly focused on interactions with patients and ensuring that
509 healthcare workers do not become infected and do not transmit infection. An integrated
510 effort is needed to further understand the requirements of healthcare workers and to
511 develop innovative materials and technologies that can meet these needs (Chapter 3).
512 Issues regarding the responsibilities of federal agencies and organizations have to be
513 clarified. Further, increasing the use of the field testing in the pre-market phase and
514 conducting thorough post-marketing evaluations is vital to the development of effective
515 products (Chapter 5).

516

517 The IOM recommendations encompass a nationwide focus for the PPT program and applicable
518 government agencies, manufacturers, and the healthcare industry. The twelve recommendations
519 made to address the three overarching conclusions are as follows:

- 520 • Understanding influenza transmission
 - 521 ○ IOM Recommendation #1: Initiate and support a global influenza research
 - 522 network. The DHHS, in collaboration with U.S. and global partners through the
 - 523 World Health Organization (WHO), should lead a multination, multicity, and
 - 524 multicenter focused research effort to facilitate understanding of the transmission
 - 525 and prevention of seasonal and pandemic influenza. A global research network of
 - 526 excellence should be developed and implemented.
- 527 • Making the commitment to worker safety and appropriate use of PPE
 - 528 ○ IOM Recommendation #6: Emphasize appropriate PPE use in patient care and in
 - 529 healthcare management, accreditation, and training. Appropriate PPE use and
 - 530 healthcare worker safety should be a priority for healthcare organizations and
 - 531 healthcare workers, and in accreditation, regulatory policy, and training.
 - 532 ○ IOM Recommendation #7: Identify and disseminate best practices for improving
 - 533 PPE compliance and use. Centers for Disease Control and Prevention (CDC) and
 - 534 the Agency for Healthcare Research and Quality (AHRQ) should support and
 - 535 evaluate demonstration projects on improving PPE compliance and use. This
 - 536 effort would identify and disseminate relevant best practices that are being used
 - 537 by hospitals and other healthcare facilities.
 - 538 ○ IOM Recommendation #8: Increase research and research translation efforts
 - 539 relevant to PPE compliance. NIOSH, the National Institutes of Health (NIH),
 - 540 AHRQ, and other relevant agencies and organizations should support research on
 - 541 improving the human factors and behavioral issues related to ease and
 - 542 effectiveness of PPE use for extended periods and in patient care-interactive work
 - 543 environments.
- 544 • Designing, testing, and certifying effective PPE for the healthcare workforce
 - 545 ○ IOM Recommendation #2: Define evidence-based performance requirements
 - 546 (prescriptive standards) for PPE. NIOSH, through the National Personal
 - 547 Protective Technology Laboratory (NPPTL), in collaboration with extramural
 - 548 researchers, manufacturers, and regulatory agencies, should define a set of
 - 549 evidence-based performance requirements or prescriptive standards for PPE to
 - 550 facilitate their design and development that optimally balances the cost, comfort,
 - 551 and degree of protection of PPE and enhances the compliance with their use in the
 - 552 field.
 - 553 ○ IOM Recommendation #3: Adopt a systems approach to the design and
 - 554 development of PPE. NIOSH should promote a systems approach to the design,
 - 555 development, testing, and certification of PPE using evidence-based performance
 - 556 requirements or prescriptive standards and fostering closer collaboration between
 - 557 the users, manufacturers, and research and regulatory agencies.
 - 558 ○ IOM Recommendation #4: Increase research on the design and engineering of the
 - 559 next generation of PPE. NIOSH, the Department of Homeland Security (DHS),
 - 560 the DoD, manufacturers, and other relevant organizations and agencies should
 - 561 fund research directed at the design and development of the next generation of

- 562 respirators, gowns, gloves, and eye protection for healthcare workers that would
563 enhance their safety and comfort.
- 564 ○ IOM Recommendation #5: Establish measures to assess and compare the
565 effectiveness of PPE. NIOSH, through NPPTL, should develop and promote a
566 validated set of measures for comparing the effectiveness of PPE products. The
567 goal is a set of measures that would allow users to compare and select appropriate
568 PPE commensurate with the assessed risk and desired level of protection.
569 Particular attention should be paid to disseminating information to healthcare
570 workers on PPE effectiveness relevant to influenza.
 - 571 ○ IOM Recommendation #9: Ensure balance and transparency of standards-setting
572 processes. Federal agencies (e.g., FDA, NIOSH, Occupational Safety and Health
573 Administration (OSHA)) should use standards developed through a consensus-
574 based transparent process that sets specific and clearly-defined limits regarding
575 conflicts of interest (financial or other) and involves broad representation of all
576 affected parties.
 - 577 ○ IOM Recommendation #10: Strengthen pre-market testing of PPE for healthcare
578 workers. FDA, NIOSH, and other relevant agencies and organizations should
579 strengthen pre-market testing requirements for healthcare PPE by requiring field
580 testing of PPE prior to approval and by reevaluating the FDA medical device
581 classification for healthcare PPE. Testing requirements should use rigorous
582 standards while also providing expeditious review of innovative approaches.
 - 583 ○ IOM Recommendation #11: Strengthen post-market evaluation of PPE for
584 healthcare workers. NIOSH, FDA, and other relevant agencies and organizations
585 should support and strengthen adverse event reporting and post-market evaluation
586 studies and surveillance regarding the effectiveness of PPE used by healthcare
587 workers.
 - 588 ○ IOM Recommendation #12: Coordinate efforts and expand resources for research
589 and approval of PPE. Congress should expand the resources provided to NIOSH
590 to further research efforts on the next generation of PPE and to coordinate and
591 expedite the approval of effective PPE. Efforts to coordinate PPE testing,
592 certification, and approval across all relevant federal agencies should include
593 developing evidence-based performance standards for all types of PPE for
594 healthcare workers.

595 Additional issues the IOM committee identified as needing to be addressed are:

- 596 ● Substantial gaps in knowledge regarding the design and implementation of PPE for
597 family members and others during an influenza pandemic
- 598 ● Challenges include the benefits of minimizing or negating fit testing of respirators,
599 protecting people with a wide range of face sizes (including children), protecting people
600 with respiratory impairment.
- 601 ● Limited oversight of PPE sold in the retail marketplace.

602

603 NIOSH/NPPTL has the overall management responsibility for the NIOSH PPT Program and is
604 responding to the IOM report by developing an action plan for addressing the issues and
605 recommendations within the PPT program domain described in the report. The action plan
606 provides both a near term and long term strategy for influenza pandemic research, development,
607 and investigative testing for the PPT Program. The action plan is structured to align with the

608 recommendations outlined in the IOM report, *Preparing for an Influenza Pandemic: PPE for*
609 *Healthcare Workers, 2007*. Each recommendation identifies current activities in progress within
610 the NIOSH PPT Program and subsequent activities which should be considered for both near
611 term and long term implementation. Associated references and web links are provided for
612 ongoing activities where available. Each text description is accompanied by a flow chart which
613 provides a pictorial representation of the information described in the associated text. Associated
614 Gantt Charts identifying anticipated timelines for conducting the activities in response to each
615 recommendation follow the flow charts. The PPT Program ongoing and potential future
616 activities are highlighted in yellow. The action plan addresses implementation of research
617 recommendations in the workplace. The following steps are being taken to develop the action
618 plan:

- 619 • Assess the IOM recommendations to identify actions within the PPT Program domain
- 620 • Review on-going and proposed PPT Program activities
- 621 • Assess the IOM recommendations to determine if existing data are available to make
622 decisions on whether the recommendations should be implemented near or long term
- 623 • Apprise applicable organizations to disseminate actions outside the PPT Program
624 domain. **Activities annotated with ** in the action plan are outside the PPT**
625 **Program domain; however some of these activities are within the scope of work**
626 **being pursued or that could be pursued by other NIOSH divisions.**
- 627 • Solicit stakeholder input on action plan.
- 628 • Review on-going activities in NIOSH, academia, government, and industry related to
629 influenza pandemic preparedness.
- 630 • Prioritize activities in response to recommendations within the PPT Program domain
- 631 • Determine if new initiatives for PPT Program should be managed through intra- or extra-
632 mural processes
- 633 • Schedule project proposals into the PPT Program strategic planning process
- 634 • Develop final PPE for HCW Action Plan
- 635 • Implement PPE for HCW Action Plan

636
637 The next two sections describe: (1) the PPT Program assessment of the projects and activities
638 which would fulfill the IOM recommendations, i.e., detailed point by point response to each
639 IOM recommendation; and (2) PPE for HCW Action Plan, i.e., prioritized 10-year plan for a
640 sequence of activities to address recommendations.

641
642 The proposed timeline to finalize the action plan is described as follows:

- 643 • Draft action plan posted to NPPTL website (February 2008)
- 644 • Present plan at stakeholder meeting (March 2008)
- 645 • Open docket to solicit comments (February 2008 – May 2008)
- 646 • Revise action plan based on comments received (August 2008)
- 647 • Propose new projects as part of PPT Program strategic planning for FY09 and beyond
648 (October 2008)
- 649 • Revise action plan based on strategic planning decisions and project outputs (November
650 2008).
- 651 • Implement action plan

652

653 The final HCW Action Plan will be used to prioritize and select future PPT Program initiatives
654 including funding, staffing, and upgrading laboratory capabilities. As noted previously,
655 activities annotated with ** are outside the PPT Program domain; however some of these
656 activities are within the scope of work being pursued or that could be pursued by other NIOSH
657 divisions.

658

659 **PPT Program PPE for HCW Action plan**

660

661 *** For the text and recommendation charts below:

662

663 Objects with yellow fill represent NPPTL



664

665

666

667 Objects with orange fill represent NIOSH



668

669


670 Objects with light purple fill represent CDC



671

672

673 Objects with light green fill represent connectivity with other recommendations



674

675

676

677
678
679
680
681
682
683
684
685
686
687
688
689

II. Assessment of Projects and Activities that align with the IOM Recommendations and Additional Issues

IOM Recommendation # 1: Initiate and Support a Global Influenza Research Network

The DHHS, in collaboration with U.S. and global partners through the WHO, should lead a multination, multicity, and multicenter focused research effort to facilitate understanding of the transmission and prevention of seasonal and pandemic influenza. A global research network of excellence should be developed and implemented.

PPT Program Plan in response to IOM Recommendation # 1

Activity #	Activity/Comment
1.1	Global Influenza Research Network
1.1.1	<p>** The near and long term opportunities for strong collaborative relationships are found at many organizational levels, including:</p> <ul style="list-style-type: none"> • Within DHHS. DHHS is the parent agency of the CDC which includes NIOSH and six Coordinating Centers/Offices. The FDA and the NIH also are located in DHHS. Within NIH, National Institute of Allergy and Infectious Diseases (NIAID) plays the lead role in influenza research. CDC is the lead U.S. agency for public health response and disease surveillance; CDC also carries out research in influenza epidemiology and molecular virology, and conducts development activities for vaccines and diagnostic tests. Within NIOSH, NPPTL has the specialized expertise relevant to PPE and Health Effects Laboratory Division (HELD) and Division of Respiratory Disease Studies (DRDS) have considerable experience in the collection and analysis of bioaerosols. FDA regulates medical devices, vaccines, and therapies, and its Center for Biologics Evaluation and Research conducts influenza research. • Across Federal Agencies. Several agencies across the Federal government are involved in activities relevant to influenza research, including the U.S. Department of Agriculture (USDA), the Department of the Interior, the DoD, the Department of State, and the U.S. Agency for International Development (USAID). • With Academia. Collaborations with academia need to continue amongst all participants to be on the fore front of new technologies. • With Private Industry. Both established pharmaceutical corporations and new start-up companies play a vital role in the development of new products and strategies for control of influenza. Efficient development of improved vaccines, therapeutics, and diagnostics therefore requires close collaboration with the private sector. • Internationally. The WHO is responsible for coordinating global influenza surveillance and the global response to an emerging influenza pandemic. DHHS is the official point of contact between WHO and the U.S. government; CDC is a designated WHO Influenza Reference Center and thus has the most extensive relationship with the WHO influenza program.
1.2	Identify and prioritize research questions with suggested possible study designs
1.2.1	Can infection take place through mucous membranes or conjunctiva exposure?
1.2.1.1	** Near term research is needed to determine the appropriate levels of protection for all viable routes of transmission.
1.2.2	What is role of UV light, humidity, temperature, pressure differentials, air flow and

exchange, and ventilation in preventing transmission?

1.2.2.1 What is the role of these environmental parameters on the effectiveness of PPE is long term research.

1.2.2.2 ** More research is needed on the effectiveness of engineering control components to regulate these environmental parameters.

1.2.2.3 NIOSH Division of Applied Research and Technology (DART) is exploring isolation controls for biological agents. The current initiative is "Expedient Patient Isolation for Bioterrorism and Epidemic Response". This project seeks to identify and provide detailed implementation guidance on expedient patient isolation techniques that can be implemented during public health emergencies and are affordable, easily implemented, provide effective isolation, reduce potential healthcare worker exposures and do not interfere with hands-on healthcare activities.

1.2.2.4 NIOSH DART is exploring isolation controls for biological agents. Another ongoing initiative is "Expedient Airborne Isolation for Emergency Response Exercises". This research will attempt to translate knowledge learned from prior research on expedient isolation within healthcare environments to non-traditional "infectious" mass casualty environments such as that which might be established in a cafeteria, gymnasium, or other shelter.

1.2.3 Do some fomites inactivate the virus and, if so, how rapidly?

1.2.3.1 NIOSH PPT Program is exploring decontamination of respirators. Current initiatives available here: Reference [A](#). Concerns over the unavailability, or decreased availability, of filtering facepiece respirators in planning exercises of a pandemic influenza have raised the question of the possibility of re-use of these respirators following decontamination. Because little data exist on this very important issue, the PPT Program has undertaken a research study looking at the effects of various methods of decontamination (e.g., chemical, soap & water, UV light, gas sterilization, microwaving, heat [e.g., autoclaving]) upon the filtration performance of filtering facepiece respirators. The data have served to identify some methods of decontamination (UV light, hydrogen peroxide) that do not affect filtration performance and could potentially be useful, whereas others (bleach, ethylene oxide, microwave) degrade the respirator somewhat (but not enough to cause filtration performance to drop below NIOSH certification standards), and others (isopropyl alcohol, soap & water, and autoclaving) excessively degrade the performance or deform the respirator. This work will also allow for the development of a standardized test protocol for measuring the sterilization efficacy of a decontamination procedure for filter medial and filtering facepiece respirators.

1.2.3.2 ** Long term research is needed to determine conditions and materials that do not support long-term survivability and viability.

1.2.4 What should the public health messages be with regard to preventing transmission (e.g., open windows, use hand sanitizers)?

1.2.4.1 PPT Program continues to conduct research and provide recommendations for the prudent use of PPE based on the best available knowledge.

1.2.4.2 NIOSH/Division of Surveillance, Hazard Evaluations and Field Studies (DSHEFS) has capabilities to provide guidance and assistance to employers and workers, including healthcare workers, addressing workplace hazards associated with pandemic influenza and aerobiological contaminants as a part of HHS pandemic influenza response plan

- responsibilities.
- 1.2.4.3 NIOSH/DSHEFS has developed a proposal for active surveillance of healthcare facilities that would assemble information relevant to a number of issues pertinent to the spread and preventive practices of influenza. Information identified for collection includes use of respirators, infection control practices, rates of infection, and infection patterns that may distinguish different types of healthcare workers. This would also have the potential to relate influenza infection patterns to various circumstances and work practices that may contribute to infection.
- 1.2.4.4 ** Long term research is needed to better define viable routes of infection and virulence, conditions that support transmissibility and conditions that support long-term survivability and viability.
- 1.2.4.4.1 HELD has recently proposed research to examine the viability of airborne influenza virus.
- 1.3 Provide priority funding to support near-term (1 to 3 years) laboratory and clinical studies of influenza transmission and prevention of seasonal influenza with particular focus on the effectiveness of types of PPE
- 1.3.1 ** Possible funding sources – CDC pandemic funds, NIH/NIAID
- 1.3.2 ** What are the major modes of transmission? How much does each mode of transmission contribute individually or with other methods of transmission?
- 1.3.2.1 ** CDC/Office of the Director/Office of Strategy and Innovation (CDC/OD/OSI)
- 1.3.2.2 New NIH Centers of Excellence identified in FY07 may be appropriate to conduct studies.
- 1.3.2.3 Potential for Office of Extramural Programs (OEP) to provide grants for studies related to transmission.
- 1.3.2.4 Results of this work are needed for PPT recommendations and serve as input to PPT Program strategic planning (research, policy, etc).
- 1.3.3 What is the size distribution of particles expelled by infectious individuals, and how does that continuum of sizes affect transmission?
- 1.3.3.1 NIOSH PPT Program has a project to characterize the particle sizes, quantity and size distribution of particles produced and expelled by coughing, the dissemination of cough-generated aerosols in the environment, and the effectiveness of disposable masks and respirators at preventing the release of cough-generated particles. Based on results, NIOSH will be proceeding to assess the affect of wearing respiratory protection when coughing and when in the presence of someone coughing. This work is summarized here [Reference B]. FY07 intramural program funding was \$269K. Results for this effort will also feed into Recommendation 1 (1.3.6).
- 1.3.3.2 ** Research on the transmission and viability of unfiltered particles is needed.
- 1.3.4 Is the virus viable and infectious on fomites and for how long? Are fomites a means of transmission and are some more able to transmit than others (i.e., viruses on respirators or cloth versus metal or wood surfaces)? What can be done to decontaminate respirators, allowing re-use under conditions of short supply?

- 1.3.4.1 Assess viability of virus on respirators. Although respirators serve to protect the wearer, concerns exist that viruses remaining on a respirator transform it into a fomite that may serve as a vehicle for infection of the wearer, or others, through handling or re-aerosolization. Utilizing the MS-2 viral E-coli bacteriophage as an influenza surrogate, the NIOSH PPT Program has undertaken a study addressing the viability of the MS-2 virus on various models of filtering facepiece respirators (including respirators with antimicrobial components). Samples of 2.5x2.5 cm² pieces of respirator filter material exposed to MS2 particles are stored for various times under optimal growth conditions. Since temperature is a major determinant for MS2 survival, samples are stored at 22°, 30°, and 37°C. After incubation for 4 hrs, 1, 2, 4 and 7 days, the samples are processed and the percentage of MS-2 survival is calculated. Data generated by this study will offer important information on fomite-related issues and also allow for the quantification of subsequent decontamination effects on the respirator. This work is summarized here: Reference [A](#).
- 1.3.4.2 ** Research on the transmissibility and viability (infectivity) of viruses is needed to quantify the level and type of controls required to protect HCW from potential fomite exposures.
- 1.3.4.2.1 CDC/National Center for Preparedness, Detection and Control of Infectious Diseases (CDC/NCPDCID) and NIAID will be apprised of the research needs.
- 1.3.4.2.2 ** PPE effectiveness study will examine survival rate of the live vaccine/virus on internal and external surfaces of the PPE as described in Reference [V](#).
- 1.3.4.2.3 These needs may be achievable under NIAID grants.
- 1.3.4.3 ** Research on the viability of viruses on materials and surfaces used for PPE other than respirators and their ability to be decontaminated is needed.
- 1.3.4.3.1 CDC and NIAID will be apprised of the research needs.
- 1.3.4.3.2 These needs may be achievable under NIAID grants.
- 1.3.5 What activities in the healthcare setting are associated with minimal or increased transmission?
- 1.3.5.1 ** Research studies, including surveillance and activity definitions, are needed to define risk levels of workplace activities and locations for influenza transmission in healthcare settings. These present both near and long term opportunities.
- 1.3.5.2 NIOSH/HELD and DRDS are working in collaboration with researchers at West Virginia University on a project to examine the potential for airborne transmission of influenza virus in a hospital emergency department. The objective of the study is to better understand the mechanisms by which influenza may be transmitted from infected patients to healthcare workers and others in a healthcare facility. During the pilot study, sampling was conducted on 8 days for 3 to 5 hours per day during influenza season. Fourteen healthcare workers were equipped with personal samplers, and 98 samplers were mounted on stands in waiting rooms, exam rooms and reception areas. Ribonucleic Acid (RNA) in the collected material was isolated, reverse-transcribed and amplified using real-time Polymerase Chain Reaction (PCR) with primers specific to Influenza A matrix protein. Influenza virus was detected in 3 of 14 personal samplers and 10 of 98 stationary samplers. Further, 50% of the virus was found on airborne particles less than 4 µm in diameter, which are small enough to stay airborne for 30 minutes or longer and to be inhaled deeply into the lungs.


Appendix A: PPE for HCW Action Plan


- 1.3.6 In light of the information that is gained on influenza transmission:
- 1.3.6.1 How effective is each type of PPE (gowns, gloves, respirators, etc.) in reducing the risk of influenza transmission (quantitative performance analysis)?
- 1.3.6.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.
- 1.3.6.1.2 A NORA funded respirator users cough study. Construction of a cough aerosol exposure simulation system will enable measurement of how well surgical masks and disposable filtering facepiece respirators protect healthcare workers from potentially infectious aerosols produced by patients during coughing, and to provide healthcare recommendations based upon the research results. A cough simulator will be built that "coughs" a simulated aerosol-laden cough through a standard head form (called the coughing head form). A second head form (called the breathing head form) will be connected to a breathing machine to simulate the inhalation and exhalation of a healthcare worker; this second head form can be outfitted with a surgical mask or respirator. The coughing and breathing head forms will be placed in a test chamber to simulate the cough of a patient and the respiration of a healthcare worker, and measure the amount of the cough aerosol that is inhaled by the breathing head form with or without a surgical mask or respirator. Five surgical masks and five respirators corresponding to those in the CDC Strategic National Stockpile, which could potentially be used to support healthcare operations in the event of a pandemic, will be tested in this project. Current initiative is described in Reference W.
- 1.3.6.1.3 Funding to develop appropriate surveillance initiatives is needed. The goal of surveillance within the PPT Program will be to develop and strengthen the use of surveillance data to identify priorities, trends, and emerging issues associated with the use of PPE/PPT in the workplace. Information gathered through the surveillance program will be used to provide baseline data on PPE/PPT use in workplaces, develop outcome measures for other NIOSH programs, help sharpen the focus of NPPTL's research program, as well as aid in the development of a more effective and active information dissemination program. The surveillance plan activities applicable to this action plan include: analysis and linking of existing databases, initial demonstration/pilot studies, and development of a sentinel system for healthcare. The aim of the Sentinel System for Healthcare is to develop an ongoing Demonstration and Sentinel Surveillance System for the ongoing monitoring of PPE/PPT (N-95, EUAE (Emergency Use Authorization Equipment) etc) selection, usage, fitting, periodicity and effectiveness in five major hospitals in the United States to evaluate and enhance timely interventional response to Pandemic Influenza, Bioterrorism and other Disasters (natural and man-made). A proposal for this work is under development.
- 1.3.6.2 How effective are medical masks?
- 1.3.6.2.1 ** Currently, performance is assessed in accordance with consensus standards' test methods as FDA cleared medical devices.
- 1.3.6.2.2 Cough project will evaluate surgical masks as described in Reference W. Also, see write-up in 1.3.3.1 for details of this project.
- 1.3.6.2.3 ** Elastic textile solution pilot for prototype masks will examine masks for potential

Appendix A: PPE for HCW Action Plan

- protection against infectious aerosols as described in Reference U.
- 1.3.6.2.4 Funding to develop appropriate surveillance initiatives is needed.
- 1.3.6.3 What innovations regarding PPE are needed to enhance effectiveness?
 - 1.3.6.3.1 NIOSH conducted workshops with RAND Jan 2004 to identify future PPE needs.
 - 1.3.6.3.2 Nov 30 - Dec1 2004 PPT Program conducted workshop to assess current state of knowledge of infectivity of bioaerosol: Workshop minutes are provided in Reference C.
 - 1.3.6.3.3 PPT Program will conduct a workshop in 2008 to assess the current state of technology. A commerce business daily presolicitation for a contractor to coordinate and conduct the workshop was published on Nov 8, 2007. [Reference D]
 - 1.3.6.3.4 ** PPE Effectiveness Study will provide scientific evidence of the efficacy of PPE (e.g. masks, respirators, eye protection) in reducing airborne transmission of influenza as described in Reference V.
- 1.4 ** Develop rigorous evidence-based research protocols and implementation plans for clinical studies during an influenza pandemic.
 - 1.4.1 Apprise CDC/NCPDCID of research needs and recommendations.
 - 1.4.2 ** Long term research is needed to better define “What percentage of patients aerosolize influenza virus during an infection?”
 - 1.4.3 ** Long term research is needed to better define “How distinct is transmission in different venues including healthcare, schools, and households?”
 - 1.4.4 ** Long term research is needed to better define “What is the time sequence of infectivity?”
 - 1.4.5 ** Long term research is needed to better define “If a person excretes virus during the presymptomatic period, is the individual infectious; is virus found in the exhaled air during normal breathing or if someone has a normal cough or sneeze (i.e., allergic cause)?”
 - 1.4.6 ** Long term research is needed to better define “When patients receive antiviral drugs do they continue to excrete virus?”
 - 1.4.7 ** Long term research is needed to better define “What is the virus concentration in saliva and nasal fluids when a person is asymptomatic, during infection, and during recovery?”
 - 1.4.8 ** Long term research is needed to better define “What is the impact of masking patients on transmission risk? If effective, how long should a medical mask be worn?”
 - 1.4.8.1 Funding to develop appropriate surveillance initiatives is needed.
 - 1.4.8.2 Cough project will evaluate surgical masks as described in Reference B. Also, see write-up in 1.3.3.1 for details of this project.

690
691
692





- 1 IOM Recommendation # 2: Define Evidence-Based Performance Requirements (Prescriptive
2 Standards) for PPE
3
4 NIOSH, through the National Personal Protective Technology Laboratory (NPPTL), in
5 collaboration with extramural researchers, manufacturers, and regulatory agencies, should define
6 a set of evidence-based performance requirements or prescriptive standards for PPE to facilitate
7 their design and development that optimally balances the cost, comfort, and degree of protection
8 of PPE and enhances the compliance with their use in the field.
9

10 ***PPT Program Plan in response to IOM Recommendation #2***

Activity #	Activity/Comment
2.1	Functionality – Protect against influenza virus, Guard against contact with contaminated fluids and aerosols.
2.1.1	Develop standards for respiratory PPE.
2.1.1.1	Identify approaches to address gaps.
2.1.1.1.1	An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.
2.1.1.1.2	NPPTL continues to certify performance of respirators through 42 CFR Part 84. NPPTL has increased its capacity for Part 84 testing of N95 respirators from 2 particulate filter penetration test instruments to 3 test instruments and a fourth instrument available as a backup or additional capacity.
2.1.1.1.3	Collaboration with Users/Other Agencies and the PPT Program.
2.1.1.1.3.1	NPPTL has a program in place with FDA to certify penetration characteristics for respirators to be designated as "Public Use Respirator for Pandemic Flu" by the FDA. Two filtering facepieces from one manufacturer are currently certified by FDA. PPT Program has an additional program in place with FDA for manufacturers seeking to make an antimicrobial claim on their FF products. PPT Program handles the particulate testing and performance evaluation, FDA makes the antimicrobial efficiency and safety determinations.
2.1.1.1.3.2	The PPT Program continues to collaborate with OSHA for coordination and support for respirator selection and use requirements during emergency as well as routine applications.
2.1.2	Develop standards for other than respirators.
2.1.2.1	Identify approaches to address gaps.
2.1.2.1.1	An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for

PPT Program Draft Healthcare Worker Action Plan
Appendix A: Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action Plan

- PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.
- 2.1.2.1.2 Other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods
- 2.1.2.1.3 Collaboration with ASTM, ISO, American National Standards Institute (ANSI) and International Safety Equipment Association (ISEA).
- 2.2 Usability – Maintain biomechanical efficiency and sense of touch and feel, odor-free, hypoallergenic, accommodate wide range of users (face and body profiles), compatibility across various elements of the PPE ensemble and with other equipment (e.g., stethoscope), non-startling to patients and families, facilitates communication with others (verbal, facial).
- 2.2.1 Develop standards for respiratory PPE.
- 2.2.1.1 Identify approaches to address gaps.
- 2.2.1.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.
- 2.2.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR Part 84.
- 2.2.1.1.3 Collaboration between ISEA and the PPT Program.
- 2.2.1.1.3.1 PPT Program anthropometric initiatives ongoing. [References [Q](#) & [R](#)]
- 2.2.2 Develop standards for other than respirators.
- 2.2.2.1 Identify approaches to address gaps.
- 2.2.2.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.
- 2.2.2.1.2 Other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods.
- 2.2.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.
- 2.2.2.1.4 DSR input for whole body anthropometrics. [Reference [T](#)]

- 2.3 Comfort and Wearability – Comfortable—no skin irritation or pressure points, Breathable—air, prolonged use without discomfort permeable, Moisture absorbent—wickability, Low bulk and weight, dimensional stability, easy to put on and take off (don and doff).
 - 2.3.1 Develop standards for respiratory PPE.
 - 2.3.1.1 Identify approaches to address gaps.
 - 2.3.1.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.
 - 2.3.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR Part 84.
 - 2.3.1.1.3 Collaboration between Users/Other Agencies and the PPT Program.
 - 2.3.1.1.3.1 The comfort of a respirator may impact the user's ability to tolerate long periods of use as would occur in the healthcare environment during a pandemic influenza. The PPT Program has served in a consultant role to the VA, which is addressing the issue of nurses' tolerability for respirators (i.e., filtering facepiece respirators, powered air-purifying respirators, half-facepiece elastomeric respirators) in a recently-completed study at the Gainesville, FL, VA hospital Intensive Care Unit. Preliminary data analysis indicates that there are two general groups of nurse users of respirators and that both have different tolerance capacities for long-term wear. This data is of potential import in situations, such as a pandemic influenza, where lengthy work shifts (e.g., >12 hours) can be anticipated.
 - 2.3.1.1.3.2 The PPT Program is undertaking a 2008 study (The Impact of Respirator Use on Carbon Dioxide and Oxygen Saturation, Project ID 921ZBFS) to determine carbon dioxide and oxygen levels in healthcare workers who wear respirators (i.e., N95FFR with and without exhalation valves, and with and without surgical mask overlay, elastomeric half-facepiece respirators) for prolonged periods as would occur in a pandemic influenza. If elevated CO2 levels or depressed O2 levels are measured that would lead to symptoms, mitigation strategies can be developed.
 - 2.3.1.1.3.3 Project on doffing garments FY10.
 - 2.3.2 Develop standards for other than respirators.
 - 2.3.2.1 Identify approaches to address gaps.
 - 2.3.2.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.

PPT Program Draft Healthcare Worker Action Plan

Appendix A: Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action Plan

2.3.2.1.2 Other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods.

2.3.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.

2.4 Durability – Adequate wear life, Strength—(tear, tensile, burst), Abrasion resistance, Corrosion resistance.

2.4.1 Develop standards for respiratory PPE.

2.4.1.1 Identify approaches to address gaps.

2.4.1.1.1 Existing and ongoing revisions of ANSI, ISO and other applicable respiratory protection consensus standards are being assessed for alignment and potential adoption by the PPT Program.

2.4.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR Part 84. [Reference [S](#)]

2.4.1.1.3 Collaboration with ISEA and PPT Program.

2.4.2 Develop standards for other than respirators. Long term research.

2.4.2.1 Identify approaches to address gaps.

2.4.2.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.

2.4.2.1.2 Other PPE performance is assessed in accordance with consensus standards' test methods.

2.4.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.

2.5 Maintenance and Reuse – Easy to decontaminate and discard disposable elements, Easy to clean and replace parts in reusable PPE.

2.5.1 Develop standards for respiratory PPE.


2.5.1.1 Identify approaches to address gaps.

2.5.1.1.1 Existing and ongoing revisions of ANSI, ISO and other applicable respiratory protection consensus standards are being assessed for alignment and potential adoption by the PPT Program.

2.5.1.1.2 NPPTL continues to certify performance of respirators through 42 CFR Part 84. [Reference [S](#)]

2.5.1.1.3 Collaboration with Users/Other Agencies and the PPT Program.

2.5.2 Develop standards for other than respirators.



2.5.2.1 Identify approaches to address gaps.

2.5.2.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods. The PPT Program has limited infrastructure for PPT research, development and investigative testing beyond respirator issues. The PPT Program is planning to expand its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party certification authorities and laboratories.

2.5.2.1.2 Other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods.

2.5.2.1.3 Collaboration with ASTM, ISO, ANSI and ISEA.

2.6 Aesthetics – Variety of styles and colors, Customizable.

2.6.1 The PPT Program and Standards Development Organizations (SDO) to develop performance –based standards to allow maximum customization and design to meet customer aesthetic desires without adversely impacting performance.

2.6.1.1 An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. NPPTL currently certifies performance of respirators, other PPE performance is assessed by third party certification authorities in accordance with consensus standards' test methods.


2.6.1.2 PPT Program will conduct a workshop in 2008 to assess the current state of technology. A commerce business daily presolicitation for a contractor to coordinate and conduct the workshop was published on Nov 8, 2007. [Reference [D](#)]


2.6.2 ** Apprise PPE manufacturers of the ability to use new technologies, and identified available technologies, to address users' aesthetic desires.

2.7 Cost - Product cost, Total life-cycle cost, Minimal environmental impact

2.7.1 PPT Program will conduct a workshop in 2008 to assess the current state of technology. A commerce business daily presolicitation for a contractor to coordinate and conduct the workshop was published on Nov 8, 2007. [Reference [D](#)]

2.7.2 ** Apprise PPE manufacturers of capabilities to increase cost effectiveness of PPE.





14 IOM Recommendation # 3: Adopt a Systems Approach to the Design and Development of PPE

15
16 NIOSH should promote a systems approach to the design, development, testing, and certification
17 of PPE using evidence-based performance requirements or prescriptive standards and fostering
18 closer collaboration between the users, manufacturers, and research and regulatory agencies.
19

20 ***PPT Program Plan in response to IOM Recommendation # 3***

Activity #

Activity/Comment

3.1 Standardize on a system safety plan with six phases (Concept, Definition, Development, Production, Deployment and Disposition). The concept phase is the initial period in which background and future technologies are developed to give a basis for the proposed system hazard analysis. The definition phase allows for verification of the initial design and engineering of the PPE. The development phase provides system input for environmental impact, PPE engineering, integration support and use studies. The production phase is where the PPE is manufactured and quality control inspection and testing is achieved. The deployment phase is where the PPE becomes available to the users and training and auditing is done. The disposition phase is where the PPE is retired and disposed of correctly.

3.1.1 Evidence based performance requirements from recommendation number two should be used as inputs into these activities.

3.1.2 Outputs from 4.3 are to be used as inputs into these activities.

3.1.3 Examine appropriate regulations for gaps where systems-approach requirements could be added to existing standards.

3.1.4 The program in place for Chemical, Biological, Radiological, and Nuclear (CBRN)/NFPA Self-Contained Breathing Apparatus (SCBA) could be considered as a model for "lessons learned".

3.1.5 Some testing required to developing a healthcare system is currently underway and will inform future options, i.e. N95 v P100, full facepiece respirator use, adhesive seal respirators, fit test evaluations [Reference E], and cough study [Reference B].


3.2 What immediate systemic or strategic measures can be taken to facilitate closer collaboration between healthcare workers (end users), PPE manufacturers, and certification or regulatory agencies on the design and development of PPE for healthcare?

3.2.1 Improved outreach approaches directed to healthcare worker PPE users, including professional societies and labor representatives, to participate and provide input in public meetings and postings of research proposals, research objectives, approval performance criteria, etc. Near term research.

3.2.1.1 Determine strategies to simulate and enhance healthcare worker participation in standards development committees, public meetings and research activities.

3.2.1.1.1 ** Funding sources need identified.

3.2.1.2 Currently, Occupational Medicine residency programs graduate < 100 physicians per year in the U.S. and many of these individuals enter academia. Many medically-related Occupational Medicine tasks (e.g., respirator fit testing, audiology testing and review, baseline pulmonary function interpretations, etc.) are overseen by Internal Medicine and




Family Medicine practitioners who may have limited training in these areas. During a pandemic influenza, demands on these practitioners regarding such issues as respirator fit testing may take on additional importance. The PPT Program has developed a one-day Occupational Medicine rotation at NPPTL, for Internal Medicine and Family Medicine resident physicians that offer instruction in such areas as audiology, respirator fit testing, and shadowing of an Occupational Medicine physician in the NPPTL Occupational Medicine clinic. This outreach endeavor will serve to increase the medical practitioner's Occupational Medicine skills and also make him/her aware of NPPTL services that may be of use to the practitioner.


3/27/2009

IOM Recommendation #3

PPT Program Response



23



24

25
26 IOM Recommendation # 4: Increase Research on the Design and Engineering of the Next
27 Generation of PPE.

28
29 NIOSH, the DHS, the DoD, manufacturers, and other relevant organizations and agencies should
30 fund research directed at the design and development of the next generation of respirators,
31 gowns, gloves, and eye protection for healthcare workers that would enhance their safety and
32 comfort.

33
34 ***PPT Program Plan in response to IOM Recommendation # 4***

Activity #	Activity/Comment
4.1	Utilizing innovations in materials such as shape memory polymers (e.g., to obviate fit testing and enhance fit of respirators and comfort of gowns) and finishing treatments (e.g., safe antimicrobial or biocidal finishes)
4.1.1	What technologies can improve fit to circumvent the need for fit testing?
4.1.1.1	NIOSH conducted workshops with RAND Jan 2004 to identify future PPE needs.
4.1.1.2	Nov 30 - Dec1 2004 PPT Program conducted workshop to assess current state of knowledge of infectivity of bioaerosol: Reference <u>C</u> .
4.1.1.3	PPT Program will conduct workshop in 2008 to assess the current state of technology. A commerce business daily presolicitation was published on Nov 8, 2007. Reference <u>D</u> .
4.1.2	What innovative designs can improve wearability issues regarding PPE?
4.1.2.1	NIOSH conducted workshops with RAND Jan 2004 to identify future PPE needs.
4.1.2.2	Nov 30 - Dec1 2004 PPT Program conducted workshop to assess current state of knowledge of infectivity of bioaerosol: Reference <u>C</u> .
4.1.2.3	PPT Program will conduct workshop in 2008 to assess the current state of technology. A commerce business daily presolicitation was published on Nov 8, 2007. Reference <u>D</u> .
4.2	Developing more effective and consistent face seals for respirators, including examination of the effect of wear and repeated donning and doffing on the quality of the face seal of filtering facepiece respirators, and research on the effect of respirator filter efficiency on face seal leakage and degree of protection
4.2.1	What are the differences in protection of N95 versus N100 or other respirators if exposed to human and avian influenza aerosols?
4.2.1.1	PPT Program is conducting research on relative performance of N95 and P100 FFRs in laboratory protection level studies. The draft protocol incorporates human subject testing planned using NPPTL generated aerosol (corn oil and sodium chloride) and ambient aerosol (PortaCount Plus) fit test facilities. Test results would be applicable to virus particles (whether aerosol or droplet transmission). Reference <u>E</u>
4.2.2	Could a nondisposable respirator be designed that could be easily decontaminated and cost-effective?
4.2.2.1	Ease of acceptable decontamination procedures are dependent on virulence of virus and effectiveness of decontamination methods.


- 4.2.2.2 Project to study antimicrobial respirator technology FY11.
- 4.2.3 Study of efficacy of user seal checks on filtering face-piece: Reference [E](#). The user seal check is required with every donning of the respirator to verify that an adequate fit has been achieved. However, the value of the user seal check has not been adequately demonstrated in the literature.
- 4.2.4 Develop a request for proposal (RFP) to solicit development of innovative products through the NIOSH/OEP.
- 4.2.4.1 ** Funding sources need to be identified.
- 4.3 Providing a seamless interface between PPE (e.g., eye protection and respirators)
- 4.3.1 Some of the lessons learned in the current project. Next Generation Structural Fire Fighting PPE Ensemble may be applicable to healthcare PPE, even though it doesn't apply to pandemic flu. Reference [E](#).
- 4.3.2 Outputs of activities should be provided as input to recommendation number three 3.1.
- 4.4 Designing respirator facepieces to integrate medical devices such as a stethoscope and to improve communication between the user and others.
- 4.4.1 ** Apprise PPE manufacturers.
- 4.5 Establishing a new set of performance requirements for Powered Air-Purifying Respirators (PAPRs) and for reusable filtering facepiece respirators that meet the needs of healthcare workers
- 4.5.1 Current PAPRs are designed to provide extremely high flow rates to protect the worker in an industrial setting. While appropriate to protect from significant dust exposures, they present serious design impediments for the healthcare worker. What are the flow rates and maximum noise levels that would be required for NIOSH to certify a PAPR that would provide adequate protection for healthcare workers? What is the risk to patients from healthcare workers wearing PAPRs (from unfiltered exhaled air), and what design modifications would be needed to eliminate such risk as well as facilitate interactions with patients?
- 4.5.1.1 PPT Program has developed concept for new PAPR certification provisions that would allow approval of 3 classes of PAPR with flow rates applicable to low, medium and high work rates. [Reference [G](#)] The concept also addresses incorporation of sensors into PPE to detect breaches and notify users of end of service life and other protection information.
- 4.5.1.2 Respirators utilized in healthcare settings were not designed for that particular venue. Therefore, there are features of respirators that do not necessarily lend themselves well to the healthcare environment. The PPT Program, in conjunction with the VA and academia initiated Project BREATHE. Currently in its developmental stages, this endeavor initially will bring together a working group consisting of healthcare workers and respirator experts from academia and government that will address respirator characteristics germane to healthcare workers (e.g., speech intelligibility, visibility, hearing, etc.) with the goal of identifying features (e.g., clear silicone components, speech diaphragms, etc.) that would enhance respirator performance in the healthcare setting. The second stage of this project would consist of bringing these recommendations to respirator manufacturers with the intent of developing a respirator


- that is designed specifically with the healthcare worker in mind. Improved respirators are likely to be better tolerated during periods of prolonged use, such as influenza pandemics.
- 4.6 Incorporating sensors into PPE to detect breaches and notify users of end of service life and other protection information. Sensors for face seal leakage is the key issue in this recommendation. If the PPE was not donned properly or no longer fitting, can this be detected and the user alerted?
- 4.6.1 Can the protection levels of the PPE worn by healthcare workers (e.g., N95 respirators) be continuously monitored during use to provide an alert to change the PPE when it is no longer effective?
- 4.6.1.1 PPT Program conducted a workshop in 2008 to assess the current state of technology. A commerce business daily presolicitation was published on Nov 8, 2007. Reference D. The workshop presentations are posted <http://cpheo.sph.umn.edu/mcohs/courses/nofit/>. A report is being prepared for NPPTL consideration.
- 4.6.1.2 PPT Program – New Sensor Technology Development for End of Service Life Indicator (ESLI): Reference H. Even though this project doesn't apply directly to pandemic flu it may be possible to use some of the lessons learned in this project and apply it to healthcare PPE (i.e. like working with manufacturers to develop sensor technology).
- 4.6.2 Develop other-than-respiratory PPE with technology to alert the user when effectiveness may be compromised.
- 4.6.2.1 Use colorimetric indicators to detect and give the PPE wearer a visual indication of exposure. These chemical reaction-based indicators are used to produce reactions to individual, or classes of compounds.
- 4.6.2.2 Develop innovative indicator systems for integration into chemical protective clothing (CPC).

3/27/2009

IOM Recommendation #4

PPT Program Response





38
39 IOM Recommendation # 5: Establish Measures to Assess and Compare the Effectiveness of PPE.
40

41 NIOSH, through NPPTL, should develop and promote a validated set of measures for comparing
42 the effectiveness of PPE products. The goal is a set of measures that would allow users to
43 compare and select appropriate PPE commensurate with the assessed risk and desired level of
44 protection. Particular attention should be paid to disseminating information to healthcare workers
45 on PPE effectiveness relevant to influenza.
46

47 ***PPT Program Plan in response to IOM Recommendation # 5***

Activity #	Activity/Comment
5.1	Expedited efforts to finalize a standardized method for measuring the total inward leakage of respirators as part of the NIOSH respirator approval protocols.
5.1.1	The NPPTL Total Inward Leakage (TIL) Program will establish TIL performance requirements and laboratory test capability for testing of PPE including all classes of respirators and protective garments. The initial TIL project will address half-mask respirator requirements and testing. Other classes of respirators will be incorporated into the program following completion of the half-mask project. Respirator TIL testing is intended to quantify the ability of respirators to fit a range of facial dimensions, representative of the US workforce. Total inward leakage testing performed under laboratory conditions represents a criterion for performance that will influence PPE design. PPT Program – TIL initiative: Reference <u>I</u> .
5.2	Develop and promote filter efficiency measures.
5.2.1	For what period of time does PPE remain contaminated with infectious influenza viruses, and what improvements can be made in doffing and decontamination procedures given that information?
5.2.1.1	Assess the viability of influenza virus on filter media: Reference <u>A</u> .
5.2.1.2	Explore efficacy in collaboration with CDC, FDA and EPA: Reference <u>A</u> .
5.2.1.3	Collaborate with PPT manufacturers: Reference <u>A</u> .
5.3	Develop and promote measures for comparing the effectiveness of respirators, gowns, gloves, eye protection, and other types of PPE based on evidence-based performance requirements.
5.3.1	NIOSH has a well established anthropometrics research program in both facial and whole body anthropometrics. The current initiatives will be examined to determine how recommendations can be addressed.
5.3.1.1	The PPT Program Facial Anthropometrics Research Roadmap was created in September 2007 and posted on the web for comment. The comment period will be open until 22 February 2008. The plan can be found here. Reference <u>R</u> .
5.3.1.2	DSR input for whole body anthropometrics ongoing activities. Reference <u>T</u> .
5.3.2	How does the penetration risk of N95 respirators made of different materials and designs change with high inhalation rates?
5.3.2.1	PPT Program will conduct workshop in 2008 to assess the current state of technology.

- A commerce business daily presolicitation was published on Nov 8, 2007. Reference [D](#).
- 5.3.3 What are the appropriate PPE decontamination strategies that would not compromise the integrity of the PPE while being easy and cost-effective to implement in a healthcare setting?
- 5.3.3.1 PPT Program is currently investigating effects of decontamination procedures on respirator performance: Reference [A](#). PPT Program to collaborate with CDC Division of Hospital Infections re: biology of virus and best possible decontamination procedures.
- 5.3.4 Do specific procedures (e.g., nebulization, endotracheal intubation, bronchoscopy, cleaning of patients' rooms) place healthcare workers at higher levels of risk of influenza infection? To what extent do various types of PPE offer protection during these procedures and processes?
- 5.3.4.1 ** (same as 1.3.5 under recommendation #1)
- 5.3.5 How does the level of protection afforded by N95 change with and without fit testing? What is the impact of masking influenza patients on transmission risk? If effective, how long before the respirator needs to be changed?
- 5.3.5.1 Describe the FDA Community use respirator and the science behind the decisions (for question 1)
- 5.3.5.2 Seasonal influenza studies should be conducted in collaboration with other NIOSH programs, CDC and NIAID.
- 5.3.6 What are the best practices for PPE removal to minimize risk of self-inoculation?
- 5.3.6.1 Assess the viability of influenza virus on filter media: Reference [A](#).
- 5.3.6.2 Explore efficacy in collaboration with CDC, FDA and EPA: Reference [A](#).
- 5.3.6.3 Collaborate with PPT manufacturers: Reference [A](#).
- 5.3.7 What are the risks of self-inoculation when changing PPE (i.e., is the true acquisition risk the same when wearing a medical mask and changing to an N95 for high-risk procedures versus wearing an N95 throughout the shift?)
- 5.3.7.1 Assess the viability of influenza virus on filter media: Reference [A](#).
- 5.3.7.2 Explore efficacy in collaboration with CDC, FDA and EPA: Reference [A](#).
- 5.3.7.3 Collaborate with PPT manufacturers: Reference [A](#).
- 5.3.8 What protective roles do gloves, gowns, and face shields or other eye protection play in preventing influenza transmission?
- 5.3.8.1 ** (same as 1.3.5 under recommendation #1)
- 5.3.9 What protection would medical masks provide to the wearer during an influenza pandemic?
- 5.3.9.1 ** (same as 1.3.5 under recommendation #1)

5.3.9.2 Currently, the performance effectiveness of medical masks is assessed in accordance with consensus standards' test methods.

5.3.10 On going PPT Program research activities

5.3.10.1 Development and validation of PPE preconditioning methods: Reference J.

5.3.10.2 Reusability of filtering facepiece respirators: Reference A.
The availability of FFR during a pandemic influenza is a subject of concern. Respirator manufacturers have warned that they may not be able to keep up with the anticipated demand. This has placed more emphasis upon the idea of decontaminating FFR for reuse. The PPT Program initiated a study in 2007 (Reusability of FFRs Exposed to Influenza Virus Simulant) to address the reusability of filtering facepiece respirators following various types of decontamination (e.g., heat, soap & water, chemicals, ultraviolet light, gas sterilization, microwaving). The data from this study have been analyzed and a manuscript prepared for journal submission. The data categorize the various decontamination agents with respect to their effects on filtration performance of the respirator.


5.3.10.3 Improve criteria for emergency medical services (EMS) protective clothing: Reference K. The PPT Program has undertaken a project to address the issue of protective clothing for EMS personnel who respond to patients with infectious diseases (approximately 1/29 of EMS calls), such as influenza, by contracting a study (Improved Criteria for Emergency Medical Protective Clothing – Project Plan Purchase Order No. 214-2006-M-15870) The objective of this project is to support the improvement of criteria for specific types of emergency medical personal protective equipment that are used by first responders. This objective specifically is defined to cover single use garments, cleaning gloves, footwear covers, and eye/face protection devices. A secondary objective of the project is to support the NFPA Technical Committee on EMS Protective Clothing and Equipment in its standards development process for modification of NFPA 1999 during its 2008 revision process. The project is intended to provide technical support for the committee to justify changes to the standard, particularly as related to changes in performance criteria.


5.3.10.4 Metabolic evaluation of N95 respirator use with surgical masks: Reference J. The IOM and the CDC have suggested that, in the face of reduced availability of filtering facepiece respirators, surgical masks placed over these respirators as a barrier might prolong their useful life. Although this recommendation has some plausibility, it has not undergone scientific scrutiny. The PPT Program initiated a study in 2006 (Metabolic Evaluation of N95 Respirator Use with Surgical Masks), utilizing an Automated Breathing and Metabolic Simulator to evaluate the concurrent use of N95FFR with surgical mask overlay. Within-respirator carbon dioxide levels, oxygen levels, and breathing resistance are being monitored to determine the effect(s) of the surgical mask on these parameters. Knowledge of these data can help predict physiological effects on wearers during prolonged periods of use, such as during a pandemic influenza. This recently-completed study (2007) by personnel from the PPT Program demonstrated that placement of a surgical mask over various models of N95FFR results in elevated breathing resistance (increases of \pm 8% - 10% during inhalation and exhalation). This mannequin-based study suggests that use of a surgical mask as a barrier over a FFR will not result in breathing resistance that will have a pronounced effect upon the wearer. The data from this study will eventually be compared with that from the current study utilizing the Automated Breathing and Metabolic Simulator (ABMS) for correlative analysis.

3/27/2009

IOM Recommendation #5

PPT Program Response





50
51 IOM Recommendation # 6: Emphasize Appropriate PPE Use in Patient Care and in Healthcare
52 Management, Accreditation, and Training.
53

54 Appropriate PPE use and healthcare worker safety should be a priority for healthcare
55 organizations and healthcare workers, and in accreditation, regulatory policy, and training.

56 ***PPT Program Plan in response to IOM Recommendation # 6***


Activity #	Activity/Comment
6.1	Healthcare employers should strengthen their organization's commitment to a culture of safety by providing leadership in worker safety; instituting comprehensive, state-of-the-art training and education programs; facilitating easy access to PPE; giving feedback to supervisors and employees on PPE adherence; and enforcing disciplinary actions for noncompliance. Near term research.
6.1.1	A commitment by healthcare employers to promoting, training, and enforcing PPE compliance could increase adherence to PPE protocols and foster the expectation and norm for appropriate PPE use.
6.1.1.1	Improved outreach approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate PPT Program recommendations and guidance. NPPTL has participated in the Association of PeriOperative Registered Nurses (AORN) conference for the last two years and will be participating with an exhibit and materials in March 2008. We also participated in the EMS Update in Champion PA in 2007 and are scheduled to return in 2008. Also exhibited at the Association of Occupational Health Professionals in 2007 and plan to return in 2008.
6.1.1.2	Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
6.2	Healthcare workers should take responsibility for their safety by working to enhance the culture of safety in the workplace and by adhering to PPE protocols.
6.2.1	A commitment by healthcare employers to promoting, training, and enforcing PPE compliance could increase adherence to PPE protocols and foster the expectation and norm for appropriate PPE use. Near term research.
6.2.1.1	Improved outreach approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate PPT Program recommendations and guidance.
6.2.1.1.1	PPT Program is currently involved in undertaking a project with members of the Association of Occupational Health Professionals in Medicine (AOHP) regarding manpower issues in annual respirator fit testing. Many AOHP members (most of whom are Registered Nurses who function within Employee Health clinics at healthcare institutions) contend that they do not have the necessary manpower to carry out OSHA-mandated annual fit testing for employees. This important issue in protecting healthcare workers takes on additional importance in the face of the increased infectious exposure that would occur during an influenza pandemic. PPT Program and AOHP members are developing a pilot program that will utilize a survey instrument (questionnaire) to determine the numbers of fit tests required per year and the available staff to carry out such testing in several local (Pittsburgh) hospitals. Data from the pilot program will be utilized to promote a larger study which will, in turn, identify manpower needs for annual fit testing in the healthcare community and how to more adequately utilize that


- manpower.
- 6.2.1.1.2 PPT Program has initiated contact with officials at the University of Pittsburgh's School of Public Health to look at areas of mutual interest with the eventuality of possibly engaging in research together.
- 6.2.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 6.2.2 How can the safety culture of healthcare facilities be improved? What approaches best facilitate a healthcare organizational culture that promotes safety? Long term research.
- 6.2.2.1 Improved collaboration between the PPT Program, OSHA, and Joint Commission on the Accreditation of Healthcare Organizations (JCAHO) to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.
- 6.2.2.2 Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 6.3 Healthcare accrediting organizations (including the Joint Commission and state health departments) should set, implement, and enforce work standards in hospitals and other healthcare facilities to ensure that proper use of PPE is a priority and a sentinel event subject to controls at the administrative, supervisory, and individual levels.
- 6.3.1 Efforts by the Joint Commission and state health departments to emphasize PPE compliance in accreditation and other assessments could focus attention on PPE issues and enhance adherence to PPE protocols.
- 6.3.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.
- 6.4 Healthcare accrediting and credentialing organizations should ensure that PPE training is part of the accreditation and testing curricula of health professional schools of nursing, medicine, and allied health and that PPE concepts and practice are included on certification examinations and as continuing education training requirements.
- 6.4.1 Efforts by the Joint Commission and state health departments to emphasize PPE compliance in accreditation and other assessments could focus attention on PPE issues and enhance adherence to PPE protocols.
- 6.4.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.
- 6.4.2 PPT Program pilot program for training on PPE use. The PPT Program has instituted an Occupational Medicine rotation at NPPTL for Internal Medicine and Family Medicine resident physicians to acclimate them to issues that are germane to their involvement in Occupation Medicine tasks.

3/27/2009

IOM Recommendation #6

PPT Program Response






59
60 IOM Recommendation # 7: Identify and Disseminate Best Practices for Improving PPE
61 Compliance and Use.
62
63 CDC and the AHRQ should support and evaluate demonstration projects on improving PPE
64 compliance and use. This effort would identify and disseminate relevant best practices that are
65 being used by hospitals and other healthcare facilities.
66

67 ***PPT Program Plan in response to IOM Recommendation # 7***

Activity #	Activity/Comment
7.1	Demonstrate, implement, evaluate, and improve the integration of worker safety into the protocols and practice of the organization.
7.1.1	** Near and long term opportunities are available for early identification influenza patients.
7.1.1.1	** These needs may be achievable under other projects or grants.
7.2	Develop, implement, and evaluate evidence-based training programs on risk assessment and the use of PPE, including addressing practical realities of wearing PPE, donning and doffing, decontamination, and waste disposal.
7.2.1	What are the best ways to train healthcare workers on appropriate use of personal protective equipment? What is the feasibility of fit testing and “just-in-time” training?
7.2.1.1	Improved collaboration between the PPT Program, OSHA, and JCAHO to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.
7.2.1.2	Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
7.2.1.2.1	PPT Program personnel recently completed a study (Mannequin-based Study of N95 FFRs Worn Concurrently With a Loose-fitting, PAPR: Effect on Protection Factors) that addressed the issue of wearing an N95FFR underneath a PAPR as is frequently done by healthcare workers performing potentially aerosol-generating procedures (e.g., suctioning, intubations, administering aerosolized medication treatments, etc.) on infectious patients, such as those with influenza. The study demonstrated that significant additional protection is afforded by this tandem respiratory combination that is especially significant in the event of PAPR failure. Publication of this data in a journal will serve to disseminate this information to the healthcare community.
7.3	Develop, implement, and evaluate worker safety communication programs focusing on infection control, PPE, and reduction of risk and barriers during an influenza pandemic.
7.3.1	What are the best mechanisms to communicate with and receive feedback from frontline healthcare workers in order to ensure that infection control measures are practical and feasible while still enhancing safety?
7.3.1.1	Improved collaboration between the PPT Program, OSHA, and JCAHO to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.

- 7.3.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 7.3.1.2.1 PPT Program personnel recently completed a study (Mannequin-based Study of N95 Filtering Facepiece Respirators Worn Concurrently With a Loose-fitting, PAPR: Effect on Protection Factors) that addressed the issue of wearing an N95FFR underneath a PAPR as is frequently done by healthcare workers performing potentially aerosol-generating procedures (e.g., suctioning, intubations, administering aerosolized medication treatments, etc.) on infectious patients, such as those with influenza. The study demonstrated that significant additional protection is afforded by this tandem respiratory combination that is especially significant in the event of PAPR failure. Publication of this data in a journal will serve to disseminate this information to the healthcare community.
- 7.3.2 Define and promote strategies to increase adherence to infection control.
- 7.3.2.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.
- 7.3.2.2 Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 7.3.2.3 PPT Program personnel recently completed a study (Mannequin-based Study of N95 Filtering Facepiece Respirators Worn Concurrently With a Loose-fitting, PAPR: Effect on Protection Factors) that addressed the issue of wearing an N95FFR underneath a PAPR as is frequently done by healthcare workers performing potentially aerosol-generating procedures (e.g., suctioning, intubations, administering aerosolized medication treatments, etc.) on infectious patients, such as those with influenza. The study demonstrated that significant additional protection is afforded by this tandem respiratory combination that is especially significant in the event of PAPR failure. Publication of this data in a journal will serve to disseminate this information to the healthcare community.
- 7.4 Monitor, enforce, and provide feedback to supervisors and employees regarding appropriate use of PPE.
- 7.4.1 ** Near and long term research is needed regarding appropriate use of PPE.
- 7.5 Evaluate and determine which practices are most effective regarding PPE use by healthcare workers, patients, and visitors, with a focus on respirator use.
- 7.5.1 How do worker safety and patient safety interact? How can priorities be balanced where they conflict?
- 7.5.1.1 Improved collaboration between the PPT Program, OSHA, and JCAHO to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.
- 7.5.1.2 Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
- 7.5.1.3 PPT Program personnel recently completed a study (Mannequin-based Study of N95





FFRs Worn Concurrently With a Loose-fitting, PAPR: Effect on Protection Factors) that addressed the issue of wearing an N95FFR underneath a PAPR as is frequently done by healthcare workers performing potentially aerosol-generating procedures (e.g., suctioning, intubations, administering aerosolized medication treatments, etc.) on infectious patients, such as those with influenza. The study demonstrated that significant additional protection is afforded by this tandem respiratory combination that is especially significant in the event of PAPR failure. Publication of this data in a journal will serve to disseminate this information to the healthcare community.

3/27/2009

IOM Recommendation #7

PPT Program Response





70
71 IOM Recommendation # 8: Increase Research and Research Translation Efforts Relevant to PPE
72 Compliance.

73
74 NIOSH, the NIH, AHRQ, and other relevant agencies and organizations should support research
75 on improving the human factors and behavioral issues related to ease and effectiveness of PPE
76 use for extended periods and in patient care-interactive work environments.

77
78 ***PPT Program Plan in response to IOM Recommendation # 8***

Activity #	Activity/Comment
8.1	Identifying effective approaches to donning and doffing PPE, including enhancements in PPE ensemble design.
8.1.1	A commitment by healthcare employers to promoting, training, and enforcing PPE compliance could increase adherence to PPE protocols and foster the expectation and norm for appropriate PPE use.
8.1.1.1	Improved outreach approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate PPT Program recommendations and guidance.
8.1.1.1.1	The PPT Program is directing its outreach approaches in several ways. An Occupational Medicine one-day rotation for Internal Medicine and Family Medicine residents of the West-Penn/Allegheny Health System is scheduled to commence Jan, 2008. It is hoped that this outreach program will enhance the practitioners' skills, some of which could be of significant importance in the face of an influenza pandemic (e.g., respirator fit testing). The PPT Program is also reaching out to medical professional societies (e.g., AOHP in Medicine) to engage them in collaborative research efforts (e.g., manpower needs for annual fit testing) that can impact aspects of a pandemic influenza. The PPT Program is also engaging healthcare systems and institutions, including the VHA and the University of Pittsburgh School of Public Health (Department of Occupational and Environmental Health) in collaborative research efforts regarding PPE. Also, NPPTL has participated in the AORN conference for the last two years and will be participating with an exhibit and materials in March 2008. We also participated in the EMS Update in Champion PA in 2007 and are scheduled to return in 2008. Also exhibited at the Association of Occupational Health Professionals in 2007 and plan to return in 2008.
8.1.1.2	Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others.
8.2	Development of standard-of-use protocols based on infection prevention and control policy with clear, simple-to-use algorithms.
8.2.1	What interventions prevent healthcare-acquired influenza?
8.2.1.1	Seasonal influenza studies related to PPT use and effectiveness should be conducted in collaboration with other NIOSH programs, CDC and NIAID.
8.3	Examination of behavioral implementation strategies for sustained use of PPE, including a focus on patient and community education as well as healthcare provider education.
8.3.1	Is a continued focus on procedure-driven PPE feasible?

PPT Program Draft Healthcare Worker Action Plan

Appendix A: Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action Plan


8.3.1.1 Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others..


8.3.1.2 Improved collaboration between the PPT Program, OSHA, and JCAHO to establish approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate and enforce PPT protocols, guidance and compliance issues.

3/27/2009

IOM Recommendation #8

PPT Program Response





81

82
83 IOM Recommendation # 9: Ensure Balance and Transparency of Standards-Setting Processes.
84
85 Federal agencies (e.g., FDA, NIOSH, OSHA) should use standards developed through a
86 consensus-based transparent process that sets specific and clearly-defined limits regarding
87 conflicts of interest (financial or other) and involves broad representation of all affected parties.
88

89 ***PPT Program Plan in response to IOM Recommendation # 9***


Activity #	Activity/Comment
9.1	Not in PPT Program domain, but in our purview.
9.2	Commit to standards setting bodies that use an open process for approvals, i.e. NFPA.

90


3/27/2009

IOM Recommendation #9

PPT Program Response



91



92

93
94 IOM Recommendation # 10: Strengthen Pre-market Testing of PPE for Healthcare Workers.
95

96 FDA, NIOSH, and other relevant agencies and organizations should strengthen pre-market
97 testing requirements for healthcare PPE by requiring field testing of PPE prior to approval and
98 by reevaluating the FDA medical device classification for healthcare PPE. Testing requirements
99 should use rigorous standards while also providing expeditious review of innovative approaches.
100


101 ***PPT Program Plan in response to IOM Recommendation # 10***


Activity #	Activity/Comment
10.1	Incorporating pre-market field testing requirements into NIOSH certification for respirators.
10.1.1	Can be done through rulemaking and/or approval processes.
10.1.1.1	Describe the Part 84 proposal in 1987 and why it was rejected and potential logistical issues.
10.1.1.2	Feasibility study should be conducted in collaboration with others to validate the need for PPE premarket testing (facilities, market share, ,etc.).
10.2	Change FDA requirements so that all healthcare PPE undergoes pre-market testing prior to approval.
10.2.1	** Pre-market testing—Immediate attention needs to be devoted in the next 6 to 12 months to determining appropriate field testing parameters and methodologies for enhancing pre-market testing of healthcare PPE to focus the testing on efficacy against transmission of infectious disease and on enhancing wearability and other critical factors for use.
10.3	** Requiring certification of other types of PPE (e.g., gowns, gloves).
10.3.1	NIOSH only has the authority to approve respirators.
10.3.2	** NIOSH does not have the authority to approve other types of PPE. However, when PPE such as gowns and gloves are considered to be medical devices, FDA has the authority to approve them.
10.3.2.1	** Have authority granted or assigned for other PPEs not already under FDA authority as medical devices.
10.3.2.2	Alternative approach -- Provide scientific expertise to standard organizations' through another agency or NIOSH PPT participation.
10.3.2.2.1	The PPT Program has several personnel who serve on various committees of Standards Organization (e.g., American National Standards Institute, International Standards Organization, etc.) to provide their valuable input. Additionally, PPE research work carried out by the PPT Program (i.e., Homeland Emergency Response Operational and Equipment Systems - HEROES project) resulted in the development of a new ASTM standard (ASTM F2668-07 Standard Practice for Determining the Physiological Responses of the Wearer to Protective Clothing Ensembles).

3/27/2009

IOM Recommendation #10

PPT Program Response





104 IOM Recommendation # 11: Strengthen Post-market Evaluation of PPE for Healthcare Workers.
105
106 NIOSH, FDA, and other relevant agencies and organizations should support and strengthen
107 adverse event reporting and post-market evaluation studies and surveillance regarding the
108 effectiveness of PPE used by healthcare workers.

109
110 ***PPT Program Plan in response to IOM Recommendation # 11***


Activity #	Activity/Comment
11.1	Workplace effectiveness studies
11.1.1	Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, other elements of CDC, and others.
11.2	Head-to-head comparison studies of the performance characteristics of PPE (including fit, filtration, and user acceptability) to allow the employer and wearer to compare and evaluate products.
11.2.1	Workplace effectiveness studies related to PPT use should be conducted in collaboration with other NIOSH programs, other elements of CDC and NIAID.
11.3	Adverse events reporting of problems with PPE use.
11.3.1	** Except for respirators apprise DHHS
11.3.2	Collaborate and share Certified Product Investigation Process (CPIP) model, used for the respirator certification program, with others: Reference <u>L</u> . The CPIP and QA models are being improved to be ISO 17025 and ISO 9001 compliant. These efforts will improve portability.
11.4	Worker health and medical surveillance where possible (e.g., infectivity rates).
11.4.1	** Funding is needed for evaluation and surveillance projects. Conducted by NIOSH programs, other elements of CDC, state health departments, and others.
11.5	Continue current respirator PPE report auditing program.
11.5.1	Collaborate and share Quality Assurance (QA) module for respirators with other PPE post market evaluations: Reference <u>M</u> . The CPIP and QA models are being improved to be ISO 17025 and ISO 9001 compliant. These efforts will improve portability.


111

3/27/2009

IOM Recommendation #11

PPT Program Response





113

114
115 IOM Recommendation # 12: Coordinate Efforts and Expand Resources for Research and
116 Approval of PPE
117
118 Congress should expand the resources provided to NIOSH to further research efforts on the next
119 generation of PPE and to coordinate and expedite the approval of effective PPE. Efforts to
120 coordinate PPE testing, certification, and approval across all relevant federal agencies should
121 include developing evidence-based performance standards for all types of PPE for healthcare
122 workers.

123
124 ***PPT Program Plan in response to IOM Recommendation # 12***


Activity #	Activity/Comment
12.1	Federal agency coordination—while each of the federal agencies has a distinct and vital role in ensuring the use of effective PPE, there is a strong need for a coordinated effort to ensure harmonization of requirements and to focus on coordinating the entire process from product design to use in the workplace. Many federal agencies in multiple departments (including the DoD, DHHS, DHS, and Labor) and the Consumer Product Safety Commission and the Environmental Protection Agency work to ensure worker safety and to approve, develop, and implement PPE.
12.1.1	An assessment of current standards needs to be conducted to categorize existing PPE as it relates to current standards. PPT Program currently certifies performance of respirators, other PPE performance is assessed in accordance with consensus standards' test methods.
12.1.1.1	PPT Program has limited infrastructure and funding for PPT research, development and investigative testing beyond respirator issues. Extensive research would be needed to develop "evidence-based performance standards for all types of PPE for healthcare workers." This would require support for both intramural and extramural research.
12.1.1.2	As resources allow, NPPTL is planning on expanding its capability in protective clothing research, development and investigative testing through training, additional personnel, and cooperative efforts with third party laboratories.

125

3/27/2009


IOM Recommendation #12

PPT Program Response



126

Recommendation #12 Timeline



127

128
129
130
131
132

IOM Recommendation # 13: Additional issues.

PPT Program Plan in response to IOM Recommendation # 13


Activity #	Activity/Comment
13.1	Substantial gaps in knowledge regarding the design and implementation of PPE for family members and others during an influenza pandemic.
13.1.1	Describe the FDA Community use respirator and the science behind the decisions: Reference <u>N</u> .
13.1.2	Improved outreach approaches directed to healthcare users and facilities, including professional societies and labor representatives to disseminate PPT Program recommendations and guidance.
13.1.3	Continuous evaluation of effectiveness of PPT Program recommendations and guidance in healthcare in collaboration with NIOSH, CDC, and others. Reference <u>O</u> .
13.2	Challenges include the benefits of minimizing or negating fit testing of respirators, protecting people with a wide range of face sizes (including children), protecting people with respiratory impairment.
13.2.1	Describe future work to evaluate the frequency of fit testing: Reference <u>P</u> .
13.2.2	Examine PPT Program on anthropometrics: Reference <u>Q</u> .
13.3	Limited oversight of PPE sold in the retail marketplace.
13.3.1	Describe the current PPT Program procedures for quality assessment: Reference <u>M</u> .


133

3/27/2009

IOM Additional Issues

PPT Program Response





135

136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181

List of References

- A. Quad chart - Reusability of Filtering Facepiece Respirators
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6PT_FY07_QC.htm
- B. Quad Chart – Aerosol Generation by Cough
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/0026_FY07_QC.htm
- C. Workshop on Respiratory Protection for Airborne Infectious Agents (30 Nov – 1 Dec 04)
<http://www.cdc.gov/niosh/npptl/resources/pressrel/announcements/113004wkshp/questions.html>
- D. Commerce Business Daily – No Fit Test Respirator Workshop Nov 8, 2007
<http://www.cbd-net.com/index.php/search/show/18235875>
- E. Quad Chart – Penetration of Nanoparticles through NIOSH-approved Respirator Filters
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z1NT_FY07_QC.htm
- F. Quad Chart – Next Generation Structural Fire Fighting PPE Ensemble Project HEROES
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z4FY_FY07_QC.htm
- G. Quad Chart – Industrial PAPR Module
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6JC_FY07_QC.htm
- H. Quad Chart – New Sensor Technology Development and Integration for End of Service Life Indicators
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/000M_FY07_QC.htm
- I. Quad Chart – Total Inward Leakage (TIL)
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/00AY_FY07_QC.htm
- J. Quad Chart – Metabolic Evaluation of N95 Respirator Use with Surgical Masks
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6PV_FY07_QC.htm
- K. Quad Chart – Improved Criteria for Emergency Medical Protective Clothing
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z1NR_FY07_QC.htm
- L. Quad Chart – Certified Product Investigation Process (CPIP)
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/PP19_FY07_QC.htm
- M. Quad Chart – Quality Assurance Module
http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z4FT_FY07_QC.htm
- N. U.S. FDA Respirators for Public Health Emergencies
<http://www.fda.gov/consumer/updates/respirators061107.html>

- 182
183 O. IOM Review of NIOSH Personal Protective Technology Program (PPT)
184 <http://www.iom.edu/CMS/3740/45683.aspx>
185
186 P. Quad Chart – Frequency of Fit Testing
187 http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z1NU_FY07_QC.htm
188
189 Q. Quad Chart – Development of Computer-Aided Face-Fit Evaluation Methods
190 http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/PP09_FY07_QC.htm
191
192 R. NPPTL Facial Anthropometrics Research Roadmap Docket # NIOSH-111
193 <http://www.cdc.gov/niosh/review/public/111/>
194
195 S. Certified Equipment List
196 <http://www.cdc.gov/niosh/npptl/topics/respirators/cel/>
197
198 T. Whole Body Anthropometrics Research
199 www.cdc.gov/niosh/nas/traumainj/pdfs/TIAppendix5NAS03-07.pdf
200
201 U. Elastic Textile Solution Pilot for Prototype Masks
202 [http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2](http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2D2008%2D49450/SynopsisP.html)
203 [D2008%2D49450/SynopsisP.html](http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2D2008%2D49450/SynopsisP.html)
204
205 V. Personal Protective Equipment (PPE) Effectiveness Study
206 [http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2](http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2D2008%2D49453/SynopsisP.html)
207 [D2008%2D49453/SynopsisP.html](http://www.fbo.gov/spg/HHS/CDCP/PGOA/Reference%2DNumber%2D000HCVKD%2D2008%2D49453/SynopsisP.html)
208
209 W. Respirator & Surgical Mask Efficacy from Cough Aerosols Project
210 See Appendix B.
211
212
213

214 **Appendix B: Respirator & Surgical Mask Efficacy from Cough Aerosols**

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

This project will be conducted in three parts: Part 1: Measure filtration performance of surgical masks and N95 respirators used in study In Part 1 of our project, all masks and respirators will be tested to determine the filtration performance of their filter media. Respirators provide protection by filtering air as it is inhaled by the wearer. The filtration performance is a measure of how well the filter media of a mask or respirator blocks the passage of particles through it. The filtration performance looks only at the filter efficiency of the mask material itself without considering any effects due to leakage through gaps in the seal between the mask and the face. For these experiments, the filtration performance will provide a common basis by which to compare the filtration abilities of the masks and respirator material, and also will provide insight as to whether particle penetration is occurring because particles are passing through the mask or respirator or are going around the mask through leaks in the face seal. Part 2: Conduct simulation experiments to evaluate exposure risk in close proximity to coughing patient The purpose of these experiments is to evaluate the potential for exposure to infectious aerosols while in close proximity to a coughing patient. These experiments are designed to simulate a “worst case” scenario by confining the cough-generated aerosol to a small space. This will allow examination of the protection offered by masks and respirators under the most challenging circumstances. These experiments will be conducted with the cough box, where the coughing head form is in one end of the box and the breathing head form in the other such that the head forms are facing each other with their mouths 2 m apart. For Part 2, an initial pilot study will be conducted using no mask, a surgical mask and an N95 respirator. After the experimental procedures have been developed and tested, a full study will be conducted using no mask, 5 types of surgical masks and 5 types of N95 respirators. Masks and respirators will be worn by the breathing head form but not by the coughing head form in order to simulate a healthcare worker exposed to an unmasked infectious patient. We will simulate a human infectious cough-generated aerosol by using a salt aerosol containing a live influenza vaccine (called FluMist) as a surrogate for the wild-type influenza virus. The amount of FluMist in collected aerosols will be measured using a quantitative PCR (qPCR) detection technique. For some experiments, fluorescein dye will be added to the aerosol fluid rather than the FluMist vaccine, and the amount of fluorescein collected will be measured using a spectrofluorometer. We anticipate that detection of the fluorescein will require collection of much larger quantities of aerosol compared to the qPCR detection of the FluMist vaccine, which will limit its use to tests with relatively high aerosol concentrations. However, the detection of fluorescein is much quicker and simpler than the qPCR technique, which makes it useful for early trials. Since the fluorescein detection and qPCR are both based on fluorescence, it may not be possible to use the two techniques at the same time. For this proposal, we will assume that sequential trials will be conducted under the same conditions for comparison. If possible, however, we will combine the two techniques. In either case, we will be able to compare the results from the fluorescein dye, the FluMist vaccine, and an optical aerosol particle counter. Part 3: Simulate exposure risk for healthcare workers in an examination room containing a coughing patient with an infectious respiratory illness The purpose of these experiments is to simulate the potential exposure of healthcare workers to an infectious aerosol generated by a coughing patient in an examination room. These experiments will be conducted using the exam room with the head forms. For the exam room, we anticipate that it will be very difficult to lower the ambient aerosol concentrations.

259 **Appendix C: Response to NIOSH Docket 129 Comments**
260 **Prepared 7-29-08.doc**

261
262 1. **Comment:**

263
264 Name: Peter A. Langes
265 Organization: Berkeley Building Education Center
266 Email: peterlanges@yahoo.com

267
268 Address
269 537 Hastings Drive
270 Benicia, CA 94510
271 USA

272
273 **Comments**

274 The concern for health care workers PPE is only as good as the attitude of the technician. There is
275 willful negligence to consider for rating the effectiveness. The SARS out break was a good
276 example of poor worker attitude, PPE was disregarded and the results were fatal.

277
278 There exist other occupations where workers have direct contact with the public 24/7 with the
279 same hazards in a open field environments. There is no sick leave in most construction and
280 plumbing jobs. workers should at least know of "universal precautions"

281
282 The problem with infectious disease is the incubation period where one is exposed and the time
283 before symptoms may or may not appear. Therefore, pandemics and epidemics and the severity
284 can be reduced by PPE training.

285
286 It is recommended that all workers that have daily contact with the public doing route work and
287 home services be required to have some form of PPE certificate of training for their occupations.
288 Since there is issue of health care costs and there is no govt health care.

289
290 The motto "prevention better than cure" by ASSE PPE is common sense in action.

291
292 Peter Langes

293
294 **Response:**

295
296 Dear Mr. Langes:

297 Thank you for your insightful comments. NIOSH is committed to reducing risk as much
298 as possible in all occupations. As you reference, there are barriers to using PPE and the
299 Healthcare Worker Action Plan addresses this through training and best practices in
300 recommendations 4, 6 and 7. Additionally, state of the art equipment design can help reduce the
301 burden on the user and will be explored in a PPT workshop being planned for November 2008.

302
303 Determining the minimum level of respiratory protection for protection against infectious
304 aerosols is an imprecise science, based on the estimated exposure hazard level and the infectious

305 dose for the general worker population. Recommendations are established based on typically
306 expected exposure and infectivity parameters. Factors such as the airborne concentration,
307 aerodynamic size, and pathogen viability in exposure scenarios are considered in assessing the
308 hazard level. These will be addressed in recommendation 1 with collaboration with other
309 organizations. The ability of the normal human immune system to resist infection and illness
310 from a pathogen is one of the factors considered in estimating the infectious dose. It would be
311 impractical to determine the effectiveness of each individual's immunity system to resist
312 infection by a given pathogen, or to develop recommended minimum levels of respiratory
313 protection based on individual variations in exposure scenarios and immunity system status.

314 Bob Janssen, MSc, ROH
315 Senior Policy Analyst
316 Prevention Policy & Regulation Review Department
317 Policy & Research Division
318 WorkSafeBC
319 Vancouver, BC, Canada
320 Phone: 604 231-8392; Fax: 604 279-7599
321 bob.janssen@worksafebc.com

322
323 Take a pledge to help raise awareness about young worker safety. Visit www.raiseyourhand.com

324
325 CONFIDENTIALITY DISCLAIMER

326
327 The information contained in this transmission may contain privileged and confidential
328 information of WorkSafeBC - the Workers' Compensation Board. It is intended for review only
329 by the person(s) named above. Dissemination, distribution or duplication of this communication
330 is strictly prohibited by all recipients unless expressly authorized otherwise. If you are not the
331 intended recipient, please contact the sender by reply email and destroy all copies of the original
332 message. Thank you.

333
334 2. **Comment:**

335
336 Thank you for providing an opportunity to provide input regarding PPE for HCWs Action Plan -
337 NIOSH Docket #129. The Council of Canadian Academies (CCA) formed an expert panel on
338 influenza & personal protective respiratory equipment last year and the expert panel report was
339 published December 2007.

340
341 As one of the panelists, I am taking this opportunity in forwarding to you for consideration the
342 2007 CCA report - Influenza Transmission and the Role of Personal Protective Respiratory
343 Equipment: an Assessment of the Evidence.

344
345 What may be interest to you is that the report tackles the question of transmission of the
346 influenza virus from a different scientific perspective, one of particle physics, respiratory tract
347 deposition, respirator versus medical mask performance; as well, the CCA report challenges
348 some traditional infectious control concepts such as the 3 foot rule, airborne versus droplet
349 transmission in recognition of problems associated with medical/infection control terminology
350 such as 'droplet nuclei', 'droplet' versus industrial hygiene terms including ballistic- / inhalable- /
351 nasopharyngeal- / tracheobronchial- / and alveolar-sized particles. The OH&S concept of the
352 hierarchy of controls is emphasized in consideration for the development and implementation of an
353 effective exposure control plan.

354
355 Of interest also is that both Drs Don Low & Lisa Brosseau - contributors to the IOM report
356 (Preparing for an Influenza Pandemic...) - were also on CCA expert panel.

357
358 <<(2007-12-19)_Influenza_PPPE_Final_Report.pdf>> <<(2007-12-19)_Report_in_Focus_-
359 _Influenza.pdf>>

360 Respectfully submitted,

361

362 **Response:**

363

364 Dear Mr. Janssen:

365 Thank you for providing us with a copy of the Council of Canadian Academies 2007
366 CCA report - Influenza Transmission and the Role of Personal Protective Respiratory
367 Equipment: an Assessment of the Evidence. We will certainly examine the report for the
368 transmission of the influenza virus and the challenges of some traditional infectious control
369 concepts as you suggested. These suggestions most aptly apply to recommendations 1 and 2.

370 Jennifer Jones
371 Product Manager, Facial Protection
372 Convertors Marketing
373 Cardinal Health
374 1500 Waukegan Road
375 McGaw Park, IL 60085
376 (Direct: (847) 785-3396
377 * jennifer.jones@cardinalhealth.com
378
379

380
381 This message is for the designated recipient only and may contain privileged, proprietary
382 or otherwise private information. If you have received it in error, please notify the sender
383 immediately and delete the original. Any other use of the email by you is prohibited.
384

385 Dansk - Deutsch - Espanol - Francais - Italiano - Japanese - Nederlands - Norsk - Portuguese
386 Svenska: www.cardinalhealth.com/legal/email
387

388 3. **Comment:**
389

390 Good Afternoon,
391

392 Thank you for the opportunity to review and provide comments on your action plan for Health
393 Care workers. As a manufacturer of health care products, especially those geared towards
394 protecting health care workers, your path forward in this space is extremely important to our
395 organization. Our health care workers are trained to be selfless to the point where oftentimes
396 they put their own health and safety at risk. It is up to us, NPPTL as a part of NIOSH and
397 Cardinal Health as a manufacturer, to ensure that we are creating and regulating products that
398 will provide the health care worker the highest level of protection possible. I am very excited
399 about the focus your group is given to this industry and look forward to the future developments
400 that will continue to unfold as a result of your focus on this industry.
401

402 To aid in your review of my comments, I will provide them based on the section of your report.
403

404 Lines 57-65: True indeed medical face masks do not provide the same level of protection as a
405 N95, but the reality is that nine times out of ten our healthcare workers are choosing a surgical or
406 procedure mask in lieu of an N95. They are relying on these products to provide the protection
407 they need for the majority of the things they are exposed to. Although they are not deemed
408 personal protective equipment by this group, they are looked at as such by the end user. I
409 challenge this group to reconsider the position taken on medical face masks or work to change
410 the regulations to ensure that an N95 is chosen every time a mask is needed.

411 Lines 508-516: I, again, challenge your group to expand your definition of PPT to include
412 medical face masks. If they aren't providing the protection today that warrants their inclusion in
413 that category then we need to create new product requirements that translate into their being
414 included into PPT and manufacturers need to adjust accordingly.

415 Lines 555-559: The standard test methods used to clear medical face masks still warrant an
416 assessment by your group. Especially, to audit whether or not they speak to actual in use
417 performance.
418

419 Humbly Submitted,
420

421
422 **Response:**
423

424 Dear Ms. Jones:

425 Thank you for your comments and interest in the action plan. NIOSH is committed to
426 reducing risk as much as possible in all occupations. As you said HCW are selfless to the point
427 where oftentimes they put their own health and safety at risk and the Healthcare Worker Action
428 Plan addresses this through training and best practices. These issues are addressed in
429 recommendations 6 and 7. Additionally, state of the art equipment design can help reduce the
430 burden on the user and will be explored in a PPT workshop being planned for November 2008.
431

432 Another concern you raised is with medical face masks and that NIOSH doesn't consider them
433 PPE and the fact that most HCWs use them in lieu of an N95. We plan to work with the FDA
434 who currently oversees medical masks and focus on ways to develop sound scientific evidence
435 from which to harmonize standards. Recommendations 2, 9 and 12 address these concerns. Our
436 research shows HCW don't use N95's because of barriers such as comfort and physiological
437 burden. These are being explored in some of our research activities. In one research project,
438 physiological burden is being explored by investigating the effects on inhaled carbon dioxide,
439 inhaled oxygen, and inhalation/exhalation pressures from the Automatic Breathing Machine
440 Simulator with the treatment of N95 particulate filtering respirators, with and without surgical
441 masks and under light, medium and heavy work rates (see
442 http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6PV_FY07_QC.htm). An article entitled
443 "Effect on breathing resistance of a surgical mask worn over an N95 filtering facepiece
444 respirator" is currently in press at The Journal of the International Society for Respiratory
445 Protection. Finally, NIOSH recently partnered with the Veterans Health Administration to
446 initiate Project BREATHE (Better Respiratory Equipment using Advanced Technologies for
447 Healthcare Employees). This project seeks to determine the ideal characteristics that would be
448 required for healthcare worker specific respirator.

449 Bill Kojola
450 Industrial Hygienist
451 AFL-CIO
452 202-637-5003
453 202-508-6978 (Fax)
454 bkojola@aflcio.org

455
456 4. **Comment:**

457
458 Dear NIOSH:

459
460 Attached are the comments we're submitting on the "Draft Personal Protective Equipment (PPE)
461 for Healthcare Workers (HCW) Action Plan", Docket No. 129.

462
463 Regards,

464
465
466 **Response:**

467
468 Dear Mr. Kojola:

469 Thank you for your very valuable comments and interest in our action plan. You bring up
470 some important concerns that we need to address:

- 471
- 472 1) Your comment about adding sneezing and talking to the "cough" simulation research has
473 been brought to the attention of the project officer and if possible will be added to the study.
474
 - 475 2) Critically examine the aerosol particle exposure 3 foot vs 6 foot rule. Mr. Janssen
476 (comment 2) provided us with a copy of the Council of Canadian Academies 2007 CCA report -
477 Influenza Transmission and the Role of Personal Protective Respiratory Equipment: an
478 Assessment of the Evidence. We will certainly examine the report for the transmission of the
479 influenza virus and the challenges of some traditional infectious control concepts as you
480 suggested and incorporate them into recommendations 1 and 5.
481
 - 482 3) Prioritize the planning and carrying out of an effectiveness assessment of antimicrobial
483 respirator technology. This is the goal of the action plan to provide NIOSH with a strategy and
484 road map in which to proceed. We realize that this is an important research and that it needs to be
485 done and will eliminate 'possible' project from the action plan. This change will be reflected in
486 recommendation 5.
487
 - 488 4) Develop a comprehensive research plan with the overall objective of developing some
489 measure of an "assigned protection factor" for respirators used to protect wearers against
490 airborne infectious agents. NIOSH is focusing on ways to develop sound scientific evidence
491 from which to harmonize PPE standards that includes the following: protecting the health and
492 safety of respirator users, providing an assurance to the user that the equipment will afford the
493 degree of protection required, and considering the person who is being required to wear the

494 protective device to accomplish their job. These concerns are being addressed in
495 recommendations 2, 5 and 7.

496
497 5) Complete as soon as possible the total inward leakage (TIL) certification requirements for
498 respirators. Currently, TIL has made its way out of NIOSH and down to HHS to start the
499 rulemaking process.

500
501 6) Assess economics and level of fit/protection of elastomeric respirators (equipped with
502 particulate filters) versus filtering facepiece respirators for use by healthcare workers who
503 provide care for pandemic flu patients. We currently have a study underway to examine fit (see
504 http://www.cdc.gov/niosh/blog/nsb042108_respiratorfit.html). The study deals mostly with
505 N95FFR types of respirators; however, we plan on doing a small study with elastomeric as well.
506 This is being done in recommendation 5.

507
508 7) Collaborate with other divisions in NIOSH to examine the wide range of options for
509 controlling worker exposure to pandemic influenza and other infectious agents. We are working
510 with Emergency Planning and Response Office (EPRO) in providing up-to-date information on
511 pandemic influenza research that can be accessed via the web (<http://www.pandemicflu.gov/>).
512 This process has started and is defined in recommendation 1.

513
514 8) Conduct research to determine the maximum use time for filtering facepiece respirators.
515 At this time, NIOSH has no ongoing or planned research on maximum use times of FFRs.
516 NIOSH realizes that this is an important research topic and recommendation 5 in the action plan
517 allows for its inclusion.

518
519 9) Develop a health care PAPR. While NIOSH is not in the business of developing
520 equipment, the PPT Program has a project (
521 http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6JC_FY07_QC.htm) on new PAPR
522 certification provisions that would allow approval of 3 classes of PAPR with flow rates
523 applicable to low, medium and high work rates. Incorporating sensors into PPE to detect
524 breaches and notify users of end of service life and other protection information. This is part of
525 the response for recommendation 4. This project will prepare a new PAPR subpart for 42 CFR
526 84 that incorporates all PAPR requirements (including CBRN) into one area. This effort will
527 result in significant improvement in PAPR requirements and the first formal incorporation of
528 CBRN requirements into the regulations and allow for the development of a healthcare PAPR.

529
530 10) Initiate, coordinate, and catalyze the work of other segments of NIOSH outside of
531 NPPTL and other federal government agencies around this action plan. The PPT Program has
532 established a work group within NIOSH to identify areas of overlap to confront potential
533 misconceptions in terms of NIOSH capabilities, identify what non-NIOSH entities should/can
534 do, and discuss what's possible in the future (see recommendation 1). After we identify our
535 capabilities, we will proceed to bring in other organizations and establish lines of communication
536 to keep abreast of on going and plan research in the PPT area.

537
538 11) Develop mechanisms for involvement of health care workers and their unions in the
539 aspects of this research plan where it will obviously be of significant benefit to outcomes. As we

540 move forward with this action plan, we will continue our outreach efforts to involve and solicit
541 information from the healthcare community through public meetings, focus group forums and
542 conferences. These are being carried out in recommendations 6, 7 and 8.

543

544 12) We found the organization of this document hard to read and at times repetitious. The
545 document was repetitious to show the overlap and interconnectivity of the recommendations and
546 that you just can't look at a recommendation by itself. We will look at ways to better organize
547 and present the information in the revised plan.

548

549 Valerie Jones, RN, BS, CIC
550 Infection Control Practitioner
551 St. Joseph's Medical Center
552 523 North Third Street
553 Brainerd, MN 56401
554 Ph: 218-828-7655
555 Fax: 218-828-3117
556 val.jones@sjmcmn.org
557

558 This e-mail communication and any attachments may contain confidential and privileged
559 information for the use of the designated recipients named above. If you are not the intended
560 recipient, you are hereby notified that you have received this communication in error and that
561 any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited.
562 As required by federal and state laws, you need to hold this information as privileged and
563 confidential. If you have received this communication in error, please notify the sender and
564 destroy all copies of this communication and any attachments.
565

566
567 **5. Comment:**
568

569 Please be very sure that there is evidence-based rationale for the use of PPE during a pan flu
570 outbreak. Please carefully consider the full impact of the fit test requirement for respirators to be
571 sure that there is scientific evidence that fit testing does, indeed, help prevent disease
572 transmission.
573

574
575 **Response:**
576

577 Dear Ms. Jones:

578 Thank you for comments and interest in the HCW action plan. It is always important for
579 PPE users to use PPE appropriate for the hazards to which they are exposed in accordance with
580 published guidance, recommendations, and regulations. Under the Action Plan, NIOSH plans on
581 establishing measures to assess and compare the effectiveness of PPE (recommendation 5), as
582 well as, focusing on ways to develop sound scientific evidence from which to harmonize PPE
583 standards (recommendation 2).

584 Lisa Tomlinson
585 Director of Government Affairs
586 Association for Professionals in Infection Control & Epidemiology (APIC)
587 1275 K Street, NW Suite 1000
588 Washington, DC 20005-4106
589 Direct Line: 202-454-2606
590 E-mail: ltomlinson@apic.org
591 Website: www.apic.org

592

593 6. **Comment:**

594

595 Comments from APIC President, Janet Frain, are attached.

596

597

598 **Response:**

599

600 Dear Ms. Tomlinson:

601 Thank you for your thoughtful comments and your offer to work with NIOSH on this
602 action plan. You bring up some important points that we should consider:

603

604 1) You said, "We greatly appreciate NIOSH's efforts to be comprehensive, but also believe
605 the need to respond to a possible epidemic in the near-term necessitates interim
606 recommendations." NIOSH agrees that interim best practices should be made available basic on
607 knowledge know now and then updated as this action plan is carried out (recommendation 7).
608 The action plan has both short and long range goals and it was never intended that
609 recommendations wouldn't be disseminated as they became known.

610

611 2) You said, "We believe that the exclusion of 'medical masks' in this plan does not address
612 the realities of how influenza virus is transmitted and the potential shortage of certified
613 particulate respirators (PR)." The action plan only states that medical masks are not considered
614 PPE. Medical masks can still part of a 'source control' effort for some people during a pandemic;
615 however since medical masks don't provide to a very good face seal, healthcare workers should
616 opt for N95FFR at a minimum. NIOSH has on going research into N95FFR decontamination and
617 the effects of using a medical mask over a N95FFR (see recommendation 5).

618

619 3) You said, "Additionally, we believe research designed to access the viability of virus on
620 respirators using a proxy should indicate whether or not the virus has survival properties after
621 surface impaction." This is a very good observation and NIOSH will clarify the study results to
622 indict what is being measured.

623

624 4) You said, "If research studies to define risk levels for influenza during workplace
625 activities in various locations are outside the scope of NIOSH research, it would be helpful to
626 indict if such studies are being done." The PPT Program has established a work group within
627 NIOSH to identify areas of overlap to confront potential misconceptions in terms of NIOSH
628 capabilities, identify what non-NIOSH entities should/can do, and discuss what's possible in the

629 future (recommendation 1). We also plan on establishing lines of communication with other
630 organizations to keep abreast of on going and plan research in the PPT area.

631

632 5) You said, "We believe NIOSH should engage with industry on the issue of certification
633 of 'out of the box' PRs." The NIOSH National Personal Protective Technology Laboratory and
634 the University of Minnesota, School of Public Health, are hosting a "No Fit Test" Respirator
635 Workshop to be held November 6, 2008 in Pittsburgh, PA to address some of the issues you raise
636 (recommendation 1 and 5). The workshop will focus on the nature and process of product
637 innovation and development in negative pressure half-face piece respirators, to gauge the current
638 "state-of-the-art," and to stimulate new designs and approaches for improved respirator fit. The
639 results of the workshop will lead to a better understanding of how future NIOSH research can
640 encourage ongoing development of better fitting respirators without compromising long-term
641 protection.

642

643 6) You said, "In addition, we applaud NIOSH research into the 'sterilization efficacy of a
644 decontamination procedure for filter media and filtering facepiece respirators' as a needed area
645 of research." We appreciate for vote of confidence for our work in this area.

646

647 7) You said, "While we appreciate the importance of NIOSH efforts to identify risks related
648 to respirator use, we also believe that a greater focus on important measures to prevent the
649 transmission of influenza and other infectious diseases is imperative." The IOM report, which
650 this action plan is based, identifies recommendations for research and policy actions in three
651 critical areas: 1) Understanding influenza transmission, 2) Commit to worker safety and
652 appropriate use of PPE, and 3) Innovate and strengthen PPE design, testing and certification.

653

654 These recommendations, while written to address issues related to pandemic influenza
655 preparedness identify initiatives necessary to determine the efficacy of PPE in preventing the
656 transmission of a variety of infectious diseases. The IOM recommendations in these critical areas
657 are extensive, requiring the involvement of numerous federal agencies, the private sector and
658 international partners (recommendation 1). The report recommends the Department of Health
659 and Human Services (HHS) lead a focused research effort to facilitate understanding of the
660 transmission and prevention of seasonal and pandemic influenza. The National Institute for
661 Occupational Safety and Health (NIOSH) is charged with assisting in this effort as it relates to
662 understanding transmission among healthcare workers, and conducting research to design and
663 promote the appropriate use of PPE (recommendation 1, 5, 6 and 7).

664

665 8) You said, "The NIOSH proposal for 'active surveillance of healthcare facilities that
666 would assemble information relevant to a number of issues pertinent to the spread and preventive
667 practices of influenza', which would include collecting information on 'use of respirators,
668 infection control practices, rates of infection, and infection patterns that may distinguish different
669 types of healthcare workers', would be very time-consuming and costly." True, surveillance is a
670 costly and time consuming business; but in order to effectively manage and direct the PPT
671 Program NIOSH needs a better PPE surveillance program to identify priorities, trends and
672 emerging issues associated with the use of PPE in the workplace. Information gathered will be
673 used to establish a baseline on PPE usage, develop performance measures, sharpen the focus of

674 NIOSH research, and aid in the development of a more effective and active dissemination
675 program (recommendations 1 and 7).

676

677 9) You said, “Additionally, recommendations relative to personal protective equipment
678 should underscore for HCWs the importance of understanding the ‘chain of infection’ and
679 portals of entry into the body.” Chain of infection is a very important topic and NIOSH in no way
680 wants to disseminate information that is in conflict with well established infection prevention
681 training in the healthcare setting. It is our goal to establish clear hierarchical recommendations
682 (discussed in 6 and 7) relative to PPE to be worn for specific tasks.

683 Kirk Bantz, RHSO

684

685 7. **Comment:**

686

687 Thank you for this effort; this article addresses many key points centered on HCW PPE in case
688 of pandemic events.

689

690 In my experience some exposure often happens before PPE is deployed when there is an
691 outbreak. This happens because the HCW is the first receiver of the first stricken by illness.
692 Depending on the organism (and your research findings) their training may have been eclipsed
693 by newer information. It is my hope that, rather than preemptive training of hundreds of
694 thousands of HCW's with less than current information, the scope of this effort could include
695 just-in-time training recommendations for HCW's PPE. Current and up-to-date training is key to
696 appropriate use of PPE. If this were to be included as an integral part of the design process, the
697 resulting use of PPE may be much more effective in protecting the HCW. Incorporation of the
698 required training into the PPE design process (as with the other performance based criteria)
699 would enhance HCW protection and help to set a standard for training in case of pandemic
700 events.

701

702 Respectfully,

703

704

705 **Response:**

706

707 Dear Mr. Bantz:

708 Thank you for your comments and interest in the HCW action plan. It is always
709 important for PPE users to use PPE appropriate for the hazards to which they are exposed in
710 accordance with published guidance, recommendations, and regulations. Under the Action Plan,
711 NIOSH plans on establishing measures to assess and compare the effectiveness of PPE
712 (recommendation 5), as well as, focusing on ways to develop sound scientific evidence from
713 which to harmonize PPE standards (recommendation 2). NIOSH is committed to reducing risk
714 as much as possible in all occupations. The Healthcare Worker Action Plan addresses this
715 through up-to-date training and best practices (recommendations 7 and 8).

716 Irwin Moyna, Director
717 Loss Control
718 Insurance & Risk Management Services
719 Trinity Health
720 248.489.6157 Direct
721 248.400.4836 Pager
722 248.488.9302 Facsimile
723 moynai@trinity-health.org
724
725 IRMS <http://content.trinity-health.org/irms/>
726

727 8. **Comment:**

728
729 Good morning,

730
731 The article addresses some key points and I am glad you are looking into HCW PPE in case of
732 pandemic events. The article does not seem to recognize the reality that for HCW's exposure
733 often happens before PPE deploys and their periodic training becomes obsolete with newer
734 information. Rather than prophylactic training hundreds of thousands of HCW's who may
735 seldom, if ever, use PPE in a pandemic event, the scope of this effort could better include just-in-
736 time training recommendations for HCW's PPE.

737
738 Training is the key component to appropriate use of PPE and we must include it as an integral
739 part of the design process to be most effective. In this way the training (and associated
740 compliance) is appropriate for the PPE. I believe incorporation of necessary training into the
741 PPE design process, in addition to the other performance based criteria, will enhance compliance
742 while setting a standard that HCW can easily comply with while conserving training resources.

743
744 **Response:**

745
746 Dear Mr. Moyna:

747 Thank you for your comments. NIOSH agrees that training is a key component to
748 appropriate use of PPE and we must include it as an integral part of the design process to be most
749 effective (recommendation 2).

750 Janice Comer Bradley, CSP
751 Technical Director
752 International Safety Equipment Association-ISEA
753 1901 N. Moore St.
754 Arlington, VA 22209
755 (703) 525-1695
756 jbradley@safetysafetyequipment.org
757 www.safetysafetyequipment.org
758

759 9. **Comment:**

760
761 Attached please find ISEA comments to the NIOSH Docket Number NIOSH-129.
762

763
764 **Response:**

765
766 Dear Ms. Comer Bradley:

767 Thank you for your informative comments and interest in this action plan. You bring up
768 some important points that we should clarify:

769
770 1) General comment 1 – Prioritization within the Action Plan

771 Prioritize activities in response to recommendations within the PPT Program domain is
772 one of the main action items we identified to achieve this action plan. Thank you for your
773 suggestions as to the key recommendations to assure resources are available.

774 As for recommendation #3, NIOSH doesn't plan to reinvent the wheel and will certainly
775 look into what is already being done in industry and incorporate it into this plan.
776

777 2) General comment 2 – Scope and Ambition of the Action Plan

778 Yes, this is a very ambitious action plan and can't be implemented in full without more
779 money and personnel. The NIOSH PPT Program has leveraged its budget quite successfully for
780 respirators and plans on continuing and improving service in this area.
781

782 3) General comment 3 – Different Certification Programs for Different Market Sectors

783 This report was written in response to the Institute of Medicine (IOM) examining
784 issues regarding PPE for healthcare workers in the event of pandemic influenza. If and
785 when this plan is implemented NIOSH will continue to serve all sectors that use PPE.
786

787 4) Request clarification on item on Page 3, line 96. Does it refer to wearer comfort in high
788 humidity environments, or the efficacy of the filtration system in these environments? This was a
789 general question that showed up in several recommendations. It deals mostly with comfort and
790 fit of the respirator in humid environments, as well as, the efficacy of the filter media.
791

792 5) These issues Section 2.2 (Page 18, line 682) are addressed by currently available respirators.
793 The respirator program manager or person doing the selection must take these issues into account
794 when selecting appropriate PPE. Recommendation #2 deals with defining a set of evidence-
795 based performance requirements or prescriptive standards for PPE to facilitate their design and

- 796 development that optimally balances the cost, comfort, and degree of protection of PPE and
797 enhances the compliance with their use in the field. The line that you referred to only was
798 describing what was meant by 'Usability'.
799
- 800 6) The clause in Section 2.2.2.1.1 (Page 18, line 705), along with several others throughout the
801 document, suggest an expansion of the scope of NIOSH activities ... Yes, that is correct. The
802 NIOSH PPT Program is looking to expand and is seeking your comments as to how to proceed.
803
- 804 7) Respirators (Page 19, line 751) are design to last for long work days (12- 16 hours) typical in
805 some heavy manufacturing industries... While that is true, the study on page 19 is looking at
806 N95FFR that would be used in an emergency such as a pandemic and available from the strategic
807 stockpile. Data is still needed for these types of respirators.
808
- 809 8) Heavy manufacturing usage requires more durability (Page 20, line 774) than health care
810 usage... See response to item #5 above.
811
- 812 9) PPE manufacturers fully understand product costs and are continually searching to reduce
813 costs ... NIOSH agrees but see response to item #5 above.
814
- 815 10) Page 24, line 892 this is a valuable program for resident physicians, and we recommend it be
816 expand to include comprehensive training in the nature, selection, use and maintenance of
817 respiratory devices in addition to proper fit testing... Thank you for you support of this program.
818 NIOSH is examining ways to improve and expand this program (recommendation 2).
819
- 820 11) Page 28, line 925 this activity regarding identifying technologies to improve fit should be a
821 lower priority in the Plan... Yes, the best policy now is to assure adequate respiratory protection
822 is in place and that the program is complete and effective. But in order to move forward and plan
823 for the future, NIOSH needs to be looking at new technologies now to start the internal processes
824 as stated in recommendations 1 and 4.
825
- 826 12) We request clarification of (Page 28, line 953) the intent and scope of this question, as there
827 are currently non-disposable respirators (ie eleatomeric respirators) available that can be
828 decontaminated... This mainly deals with decontamination of N95FFRs. Again, this is specific
829 to if a pandemic were to occur and one may have to use a respirator more than what was
830 originally intended.
831
- 832 13) The user seal check (Page 29, line 958) is important, as it requires the user to evaluate fit in a
833 subjective way every time he dons the respirator... Thank you for your comment and we have
834 made a note about the user seal check cannot be a substituted for formal fit testing.
835
- 836 14) We are concerned that this statement (Page 29, line 971) implies that medical devices would
837 be considered accessories to the respirator in the respirator certification process... At this time,
838 NIOSH doesn't plan on approving medical devices. This was meant more to stimulate research
839 on better ways to improve communications between HCW and patients, etc. Thus, we are
840 looking at new designs and engineering efforts in recommendation 4.
841

842 15) We disagree with the broad statement (Page 29, line 989). There are devices currently on the
843 market that have been designed with healthcare sector specifically in mind... This dealt with the
844 PAPR specifically and how there is a need to have a low flow class. We will clarify this in the
845 next write up.

846
847 16) Request clarification on colorimetric and innovative indicator as we don't know the meaning
848 of these two items. The descriptions of these two items were unintentionally left out and will be
849 added in the next revision. Thank you for catching this. Colorimetric and innovative indicator
850 refers to chemical reaction-based indicators that are used to produce reactions to individual, or
851 classes of compounds. The reactions, such as visible color changes or other easily noted
852 indications, are used to detect and give the PPE wearer a visual indication of exposure.

853
854 17) NIOSH should evaluate breathing resistance of N100 respirator against that of the N95
855 respirator covered with a surgical mask... Thanks for the suggestion. One of the reasons we are
856 looking at the N95s is because they are in the strategic stockpile, but your comment about N100
857 not creating physiological effects for users based on your experience is valuable
858 (recommendations 4 and 5).

859
860 18) We disagree with this proposal (Page 53, line 1448) regarding incorporation of pre-market
861 field testing in NIOSH certification for respirators. This was just a suggestion and at this time
862 NIOSH has no plans to do pre-testing of respirators. Thanks for you comment.

863
864 19) We object to this proposal (Page 53, line 1461 certification for other PPE) for PPE currently
865 addressed by consensus standards... There is a strong push to look into certifying other types of
866 PPE. It is an issue that we need to address more fully as discussed in recommendation 2.

867
868 20) ISEA supports Workplace effectiveness studies which determine the effectiveness of
869 respiratory protection for protection against micro-organisms... Thanks for your comment and
870 we agree that reliable methods need to be developed for measuring concentrations and viability
871 of micro-organisms inside and outside the respirator.

872
873

874 Mr. Borwegen
875
876 10. **Comment:**

Re: 10/10/08



May 27, 2008

NIOSH Docket No. 129
NIOSH Mailstop C-34
Robert A. Taft Laboratory
1676 Columbia Parkway
Cincinnati, OH 45226

Re: Personal Protective Equipment (PPE) for Healthcare Workers (HCW)
Action Plan, Docket No. 129

Dear Sir or Madam:

The Service Employees International Union (SEIU) appreciates the opportunity to provide comments to NIOSH on its draft document, Personal Protective Equipment (PPE) for Healthcare Workers (HCW) Action Plan. We're very pleased that NIOSH is preparing this research action plan in response to the Institute of Medicine's (IOM) report, *Preparing for An Influenza Pandemic: Personal Protective Equipment for Healthcare Workers*. The IOM's findings and recommendations for additional research on understanding influenza transmission, the need to improve the use of PPE and create a culture of safety in the healthcare industry, and strengthening PPE design and testing are critically important for advancing the protections that healthcare workers will need from PPE when the pandemic occurs.

Our nation's ability to respond effectively in providing care for patients with pandemic flu is squarely on our ability to protect the health and safety of health care workers responsible for giving that care. While PPE will play a substantial part in the effort to protect health care workers, the full hierarchy of controls will need to be implemented, first, engineering approaches (such as isolation rooms and UV lights) and secondly, applying administrative measures (such as minimizing the number of workers in an infected patients room). PPE will represent the last, and least effective, element of the exposure control hierarchy. Given the IOM's concern about the general lack of a safety culture in this industry, we believe NIOSH should clearly place this PPE research action plan within a larger plan to examine the current status of prevention efforts in this industry and provide recommendations for the entire hierarchy of controls. NIOSH has done excellent work on such reports on various industries in the past and these have been very useful in improving health and safety conditions.

ANDREW L. STERN
International President

ANNA V. JACOB
International Secretary-Treasurer

MARY KAY ELLIOTT
Executive Vice President

GERRY HILLMAN
Executive Vice President

EUSEBIO MEDINA
Executive Vice President

TOM WOODRUFF
Executive Vice President

SERVICE EMPLOYEES
INTERNATIONAL UNION
CFR/CJC

1800 MIZOPULSITS Pkwy NW
Washington, DC 20036

202 736 7200
Toll: 777 736 7151
www.SEIU.org

877

878 **Response:**

879

880 Dear Mr. Borwegen:

881 Thank you for your informative comments and interest in this action plan. Our response
882 to your suggestions follows:

883

884 1) Your comment about adding sneezing and talking to the “cough” simulation research has
885 been brought to the attention of the project officer and if possible will be added to the study.

886

887 2) Critically examine the aerosol particle exposure 3 foot vs 6 foot rule. Mr. Janssen
888 (comment 2) provided us with a copy of the Council of Canadian Academies 2007 CCA report -
889 Influenza Transmission and the Role of Personal Protective Respiratory Equipment: an
890 Assessment of the Evidence. We will certainly examine the report for the transmission of the
891 influenza virus and the challenges of some traditional infectious control concepts as you
892 suggested and incorporate them into recommendations 1 and 5.

893

894 3) Prioritize the planning and carrying out of an effectiveness assessment of antimicrobial
895 respirator technology. This is the goal of the action plan to provide NIOSH with a strategy and
896 road map in which to proceed. We realize that this is an important research and that it needs to be
897 done and will eliminate ‘possible’ project from the action plan. This change will be reflected in
898 recommendation 5.

899

900 4) Develop a comprehensive research plan with the overall objective of developing some
901 measure of an “assigned protection factor” for respirators used to protect wearers against
902 airborne infectious agents. NIOSH is focusing on ways to develop sound scientific evidence
903 from which to harmonize PPE standards that includes the following: protecting the health and
904 safety of respirator users, providing an assurance to the user that the equipment will afford the
905 degree of protection required, and considering the person who is being required to wear the
906 protective device to accomplish their job. These concerns are being addressed in
907 recommendations 2, 5 and 7.

908

909 5) Complete as soon as possible the total inward leakage (TIL) certification requirements for
910 respirators. Currently, TIL has made its way out of NIOSH and down to HHS to start the
911 rulemaking process.

912

913 6) Assess economics and level of fit/protection of elastomeric respirators (equipped with
914 particulate filters) versus filtering facepiece respirators for use by healthcare workers who
915 provide care for pandemic flu patients. We currently have a study underway to examine fit (see
916 http://www.cdc.gov/niosh/blog/nsb042108_respiratorfit.html). The study deals mostly with
917 N95FFR types of respirators; however, we plan on doing a small study with elastomeric as well.
918 This is being done in recommendation 5.

919

920 7) Collaborate with other divisions in NIOSH to examine the wide range of options for
921 controlling worker exposure to pandemic influenza and other infectious agents. We are working
922 with Emergency Planning and Response Office (EPRO) in providing up-to-date information on

923 pandemic influenza research that can be accessed via the web (<http://www.pandemicflu.gov/>).
924 This process has started and is defined in recommendation 1.

925

926 8) Conduct research to determine the maximum use time for filtering facepiece respirators.
927 At this time, NIOSH has no ongoing or planned research on maximum use times FFR's. NIOSH
928 realizes that this is an important research topic and recommendation 5 in the action plan allows
929 for its inclusion.

930

931 9) Develop a health care PAPR. While NIOSH is not in the business of developing
932 equipment, the PPT Program has a project (
933 http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6JC_FY07_QC.htm) on new PAPR
934 certification provisions that would allow approval of 3 classes of PAPR with flow rates
935 applicable to low, medium and high work rates. Incorporating sensors into PPE to detect
936 breaches and notify users of end of service life and other protection information. This is part of
937 the response for recommendation 4. This project will prepare a new PAPR subpart for 42 CFR
938 84 that incorporates all PAPR requirements (including CBRN) into one area. This effort will
939 result in significant improvement in PAPR requirements and the first formal incorporation of
940 CBRN requirements into the regulations and allow for the development of a healthcare PAPR.

941

942 10) Initiate, coordinate, and catalyze the work of other segments of NIOSH outside of
943 NPPTL and other federal government agencies around this action plan. The PPT Program has
944 established a work group within NIOSH to identify areas of overlap to confront potential
945 misconceptions in terms of NIOSH capabilities, identify what non-NIOSH entities should/can
946 do, and discuss what's possible in the future (see recommendation 1). After we identify our
947 capabilities, we will proceed to bring in other organizations and establish lines of communication
948 to keep abreast of on going and plan research in the PPT area.

949

950 11) Develop mechanisms for involvement of health care workers and their unions in the
951 aspects of this research plan where it will obviously be of significant benefit to outcomes. As we
952 move forward with this action plan, we will continue our outreach efforts to involve and solicit
953 information from the healthcare community through public meetings, focus group forums and
954 conferences. These are being carried out in recommendations 6, 7 and 8.

955

956 12) We found the organization of this document hard to read and at times repetitious. The
957 document was repetitious to show the overlap and interconnectivity of the recommendations and
958 that you just can't look at a recommendation by itself. We will look at ways to better organize
959 and present the information in the revised plan.

960

961 Nancy J. Olins, MA
962 Policy and Strategic Initiatives Manager
963 Society for Healthcare Epidemiology of America (SHEA)
964 1300 Wilson Blvd., Suite 300
965 Arlington, VA 22209
966 ph: (703) 684-0761
967 fax: (703) 684-1009
968 nolins@shea-online.org

969
970 11. **Comment:**

971
972 Attached please find The Society for Healthcare Epidemiology of America (SHEA) comments
973 on Personal Protective Equipment (PPE) for Healthcare Workers Action Plan Docket #129.
974 Thank you for the opportunity to comment.

975
976
977 **Response:**

978
979 Dear Ms. Olins:

980 Thank you for your informative comments and interest in this action plan. Our response
981 to your suggestions follows:

982
983 1) You are concerned that the report assumes that NIOSH certified respirators should remain the
984 minimal standard for respiratory protection during and influenza pandemic...
985 Determining the minimum level of respiratory protection for protection against infectious
986 aerosols is an imprecise science, based on the estimated exposure hazard level and the infectious
987 dose for the general worker population. Recommendations are established based on typically
988 expected exposure and infectivity parameters. Factors such as the airborne concentration,
989 aerodynamic size, and pathogen viability in exposure scenarios are considered in assessing the
990 hazard level. The ability of the normal human immune system to resist infection and illness from
991 a pathogen is one of the factors considered in estimating the infectious dose. These type of topics
992 are covered in recommendation 1. Our research shows HCW don't use N95's because of barriers
993 such as comfort and physiological burden. These are being explored in some of our research
994 activities (recommendation 5). In one research project, physiological burden is being explored by
995 investigating the effects on inhaled carbon dioxide, inhaled oxygen, and inhalation/exhalation
996 pressures from the Automatic Breathing Machine Simulator with the treatment of N95
997 particulate filtering respirators, with and without surgical masks and under light, medium and
998 heavy work rates (see http://www.cdc.gov/niosh/nas/ppt/QUADCharts07/Z6PV_FY07_QC.htm).
999 An article entitled "Effect on breathing resistance of a surgical mask worn over an N95 filtering
1000 facepiece respirator" is currently in press at The Journal of the International Society for
1001 Respiratory Protection. Finally, NIOSH recently partnered with the Veterans Health
1002 Administration to initiate Project BREATHE (Better Respiratory Equipment using Advanced
1003 Technologies for Healthcare Employees). This project seeks to determine the ideal
1004 characteristics that would be required for healthcare worker specific respirator. Also, NIOSH is
1005 researching the sterilization efficacy of a decontamination procedure for filter media and filtering
1006 facepiece respirators (recommendation 2).

1007

1008 2) You acknowledge the joint responsibilities of NIOSH and the FDA in certifying the
1009 manufacture and use of both masks and respirators. You note that the FDA has previously
1010 approved N95 type respirators for public use during an influenza pandemic without regard to the
1011 need for prior fit-testing. You want NIOSH to review the successful practice in Europe of
1012 certifying respirators for both filtration capability and facial fit without the need for fit-testing...
1013 We plan to work with the FDA who currently oversees medical masks and focus on ways to
1014 develop sound scientific evidence from which to harmonize standards. Recommendations 2, 9
1015 and 12 address these concerns. The NIOSH National Personal Protective Technology Laboratory
1016 and the University of Minnesota, School of Public Health, are hosting a "No Fit Test" Respirator
1017 Workshop to be held November 6, 2008 in Pittsburgh, PA to address some of the issues you
1018 raise. The workshop will focus on the nature and process of product innovation and development
1019 in negative pressure half-face piece respirators, to gauge the current "state-of-the-art," and to
1020 stimulate new designs and approaches for improved respirator fit. The results of the workshop
1021 will lead to a better understanding of how future NIOSH research can encourage ongoing
1022 development of better fitting respirators without compromising long-term protection
1023 (recommendations 4 and 5).

1024

1025 3) You are pleased that NIOSH/NPPTL did not limit their response to the IOM report to
1026 respiratory protection. You agree that a comprehensive review of PPE in healthcare settings is
1027 overdue including PPE utilized during both routine and emergency circumstances... It is always
1028 important for PPE users to use PPE appropriate for the hazards to which they are exposed in
1029 accordance with published guidance, recommendations, and regulations. Under the Action Plan,
1030 NIOSH plans on establishing measures to assess and compare the effectiveness of PPE
1031 (recommendation 5), as well as, focusing on ways to develop sound scientific evidence from
1032 which to harmonize PPE standards (recommendation 2). Also, NIOSH is building a surveillance
1033 program to identify priorities, trends and emerging issues associated with the use of PPE in the
1034 workplace. Information gathered will be used to establish a baseline on PPE usage, develop
1035 performance measures, sharpen the focus of NIOSH research, and aid in the development of a
1036 more effective and active dissemination program (recommendation 1). As you reference, there
1037 are barriers (like unpredictable contacts between patients and HCW, the need for unimpeded
1038 communications and financial stress on the healthcare industry) to using PPE and the Healthcare
1039 Worker Action Plan addresses this through training and best practices (recommendations 7 and
1040 8).

1041

1042 **Appendix D: List of Acronyms**

1043		
1044	A	
1045	ABMS	Automated Breathing and Metabolic Simulator
1046	AFRL	Air Force Research Lab (Wright-Patterson AFB)
1047	AHRQ	Agency for Healthcare Research and Quality
1048	ANSI	American National Standards Institute
1049	AOHP	Association of Occupational Health Professionals
1050	AORN	Association of periOperative Registered Nurses
1051	ASTM	American Society for Testing and Materials International
1052		
1053	B	
1054	BREATHE	Better Respirator Equipment and Technology for Healthcare Employees
1055	BSC	Board of Scientific Counselors
1056		
1057	C	
1058	CBRN	chemical, biological, radiological, and nuclear
1059	CDC	Centers for Disease Control and Prevention
1060	CFR	Code of Federal Regulations
1061	CO ₂	Carbon Dioxide
1062	COPPE	Committee on Personal Protective Equipment
1063	CPC	Chemical Protective Clothing
1064	CPIP	Certified Product Investigation Process
1065		
1066	D	
1067	DART	Division of Applied Research and Technology
1068	DHHS	Department of Health and Human Services
1069	DHS	Department of Homeland Security
1070	DoD	Department of Defense
1071	DRDS	Division of Respiratory Disease Studies (NIOSH)
1072	DSHEFS	Division of Surveillance, Hazard Evaluations and Field Studies (NIOSH)
1073		
1074	E	
1075	EMS	emergency medical services
1076	EPA	Environmental Protection Agency
1077	ESLI	End of Service Life Indicator
1078	EUAE	Emergency Use Authorization Equipment
1079		
1080	F	
1081	FDA	U.S. Food and Drug Administration
1082	FFR	filtering facepiece respirator
1083	FY	fiscal year
1084		
1085	G	
1086		
1087	H	
1088	HCW	Healthcare Worker
1089	HELD	Health Effects Laboratory Division/NIOSH
1090	HEROES	Homeland Emergency Response Operational and Equipment Systems
1091	HHS	Health and Human Services
1092		
1093	I	
1094	IOM	Institute of Medicine
1095	IP	Implementation Plan
1096	ISEA	International Safety Equipment Association

Appendix D: List of Acronyms

1097	ISO	International Organization for Standardization
1098		
1099	J	
1100	JCAHO	Joint Commission on the Accreditation of Healthcare Organizations
1101		
1102	K	
1103	K	Thousand
1104		
1105	L	
1106		
1107	M	
1108		
1109	N	
1110	NA	the National Academies
1111	NCPDCID	National Center for Preparedness Detection and Control of Infectious Diseases
1112	NFPA	National Fire Protection Association
1113	NIAID	National Institute of Allergy and Infectious Diseases
1114	NIH	National Institute of Health
1115	NIOSH	National Institute for Occupational Safety and Health
1116	NORA	National Occupational Research Agenda
1117	NPPTL	National Personal Protective Technology Laboratory
1118		
1119	O	
1120	O ₂	Oxygen
1121	OD	Office of the Director
1122	OEP	Office of Extramural Programs
1123	OSHA	Occupational Safety and Health Administration (DOL)
1124	OSI	Office of Strategy and Innovation
1125		
1126	P	
1127	PAPR	powered air-purifying respirator
1128	PCR	Polymerase Chain Reaction
1129	PPE	personal protective equipment
1130	PPT	personal protective technology
1131		
1132	Q	
1133	QA	Quality Assurance
1134		
1135	R	
1136	RFP	Request for Proposals
1137	RNA	Ribonucleic Acid
1138		
1139	S	
1140	SARS	Severe Acute Respiratory Syndrome
1141	SCBA	self-contained breathing apparatus
1142	SDO	Standards Development Organizations
1143		
1144	T	
1145	TIL	total inward leakage
1146	TSWG	Technical Support Working Group
1147		
1148	U	
1149	USAID	U.S. Agency for International Development
1150	USDA	U.S. Department of Agriculture
1151		
1152	V	

Appendix D: List of Acronyms

1153	VA	U.S. Department of Veterans Affairs / Veterans Health Administration
1154		
1155	W	
1156	WHO	World Health Organization
1157		
1158	Y	
1159		
1160	Z	
1161		
1162		
1163		
1164		